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ABSTRACT
DESIGN OF NOVEL DRUG DELIVERY SYSTEM
AND OPTIMAL DOSAGE REGIMENS
by
Kwang Seok Kim
Three representative drug delivery systems were analyzed to emphasize the roles of math-
ematical models and computer-aided simulations in pharmaceutical research. In the first
project, a protocol was developed so that the optimal regimen, consisting of the intravenous
boluses and subsequent infusion of theophylline, could be obtained once information on the
pharmacokinetics became available. The method was based on a two-compartment model
of the human body. A module was created and posted on a website for free access. The
second project dealt with the transdermal heat-assisted delivery of corticosterone. Heat
conduction and drug diffusion through the patch and the skin were expressed in the math-
ematical model. Four design parameters were estimated. This model was validated using
clinical data from the administration of fentanyl. Cortisone concentrations through the
patch and skin layers were predicted. The results were used to rank the relative impacts
of the design parameters on the corticosterone delivery and to make proper suggestions
for fabricating the products. Finally, the simultaneous application of an electric current
and soluble microneedles were proposed for the first time. Preliminary experimental stud-
ies suggested that the electric field enhanced the flux by increasing drug diffusion and,
thereby, the dissolution of the microneedles. One-, two- and three-dimensional simula-
tions were conducted. In addition, protocols were proposed to help with the analysis of
laboratory data.
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This work focuses on the development of mathematical models and the application of con-
trol protocols to gain a better understanding of drug delivery platforms. The use of analyt-
ical tools in the design controlled-release devices allows drug manufacturers, pharmaceu-
tical scientists and medical professionals to evaluate molecular transport through various
biological barriers. In addition, they may be able to monitor drug concentration profiles in
the plasma and link a desired release profile to the formulation composition. The modeling
and design approach is based on the application of mass, energy and momentum balances
to elucidate pertinent transport mechanisms. Computer simulations serve as virtual non-
invasive sensors which provide continuous and non-invasive measurements when physical
devices are unsuitable, unavailable or difficult to install. For example, in the transder-
mal delivery of a pain killer, the drug level in the serum or present in the patch are easily
measured off-line. However, no sensor has been developed to capture the spatial distribu-
tion of drugs through the thin dermal layers. In this case, such a profile can be deduced
from mathematical models and measured quantities (e.g., blood plasma drug concentra-
tion) which agree well with other measurable quantities [1]. The development of a state
estimator, made possible by a fundamental knowledge of the system and computer simu-
lations, may allow researchers to identify the effects of changes in individual or lumped
design variable(s) on the comprehensive therapy [2, 3].
In light of these advantages, each of three following chapters in this dissertation
is focused on the derivation and applications of models describing pharmacokinetics and
their implications for new delivery platforms. In Chapter 2, the optimization protocol for
the best regimens, including two different intravenous dosage forms, is developed. Bolus
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dosage of a drug allows the instantaneous increase in the serum concentration, but patients
need to endure unpleasant pains from hypodermal needles as they take medications [4].
On the other hand, infusion provides constant-rate administration of a drug with only a
one-time administration. However, patients may have to wait a long time until the serum
concentration reaches the minimum therapeutic level so that the medication goes into effect
[5]. The proposed protocol implements both dosage forms in a treatment schedule and finds
the best regimens, i.e., bolus dose sizes and times at which boluses are injected or infusion
starts.
In Chapter 3, the process design of a transdermal corticosterone delivery patch en-
hanced by an external heating source is considered. A corticosterone is a steroid hormone
which takes part in regulation of behaviors, life boundaries and even appetite of mammals
including human [6]. Since a human body needs only small amounts of such hormones, the
transdermal route may be a good candidate to a long-time corticosterone treatment. How-
ever, the only drawback of the transdermal patch is a delayed therapeutic effect due to the
slow passage of drug through skin [7]. To overcome this, temperatures of patch and skin
are slightly elevated by covering the patch with a heating pad [8, 9]. Higher temperature
allows drug material to penetrate membranes of the patch and the skin easily, and thus,
faster release of corticosterone, i.e., earlier therapeutic effect, can be achieved. Chapter 3
is devoted to the identification of main design factors of such drug delivery protocol for the
safe and effective purposes.
Finally, in Chapter 4, parallel use of electric field in a self-dissolving microneedle
patch is proposed. The stratum corneum is an outermost layer of skin which acts as a
formidable barrier to transdermal drug delivery [7]. An array of microneedles makes small
holes on the stratum corneum through which drug is released [10]. There is no pain due to a
micro-sized needle, and fast penetration of drug can be achieved. An advanced application
implements a water-soluble material mixed with drug in the fabrication of microneedles so
that, once the needle is put under the stratum corneum, it starts to be degraded releasing
3
enclosed drug into epidermis/dermis layers [11]. For even faster and controllable release,
the use of an electric field is proposed in this dissertation. An attempt to include an ion-
tophoresis in the self-dissolving microneedle technique was already made [12]. In that
platform, an electric current was applied at the skin surface after the patch had been worn
and removed [12]. In the newly proposed system, however, the electrode has the similar
shape as the microneedle. An array on a patch contains self-dissolving microneedles and
electrodes located in alternate sequences. Once a patch is worn, the circuit is closed, and
thus, space charges carry medications in the parallel directions to the skin in addition to
passive diffusion. This eliminates drug around the needles faster and results in quicker dis-
solution of the needles. Since this platform has not been considered before, the proposed
concept is first tested through preliminary studies. Then, the mathematical model is set up
for one-, two- and three-dimensional simulations. The results are used to make guidelines
for further experiments and products.
Concluding remarks about the roles of mathematical modeling and simulations in
drug delivery technology are offered in Chapter 5. The solutions of partial differential equa-
tions shown in Chapters 2, 3 and 4 may be able to be solved more conveniently using com-
mercial softwares. However, the current budgetary situations of most small pharmaceutical
companies do not allow them to purchase such expensive softwares, and they do not have
expertise on computer programming to use the tools. In light of this dilemma, all programs
used to solve the problems in this dissertation are written in the Mathematica® (Wolfram
Research, Inc.) environment for the purpose of free public access. Once a Mathematica®
code for solving a problem is prepared, it will be posted online in the form of an interactive
dialogue powered by webMathematica® so that an anonymous user can put his/her data
from experiments or pertinent information into given spaces on the webpage and obtain the
results of simulations by clicking a submit button. In that computing paradigm, knowledge
of engineering, mathematics or programming language is not required.
4
1.2 Motivations
The primary goals of this dissertation are to advance the state of knowledge in drug deliv-
ery and collaborate with Big Pharma as well as small pharmaceutical companies around
the world. Studies on the global health care conditions are conducted in 2006 by the World
Health Organization (WHO). According to the statistics, health care expenses are not lead-
ing indicators of life expectancy; people around the world suffer from a range of diseases
during a significant fraction of their lives in spite of large investments in health care. De-
veloped countries spent a larger portion of their GDP on health care than the developing
and the undeveloped countries did (Figure 1.1). The only exception to this trend is New
Zealand. Although the United States spends the highest percentage of its GDP on im-
proving health condition of its population, most Americans do not live healthier lives than
people from the other countries. Figure 1.2 represents the Life Expectation at Birth (LEB)
and the Healthy Life Expectation at Birth (HLEB) for the countries listed in Figure 1.1.
The LEBs of the United States were 75 years for males and 80 years for females in
2006. These numbers are smaller than those in Canada, the United Kingdom, Japan and
New Zealand which spend a lower share of their GDP on health. In addition, the country
with the highest LEB (i.e., Japan) spends nearly eight percent of its GDP on health (fifth
in expenditures as % of GDP). It is also evident, from these findings, that people, by and
large, suffer from various forms of illness for a total of 10 years during their life spans.
The quality of modern health services has improved from that of hundreds years
ago. The invention of digital computers and many imaging instruments helps healthcare
providers to cumulate medical knowledge, diagnose quickly and accurately the diseases
from which their patients suffer, and conduct surgical operations safely. In addition, the
developments in biosciences such as biology, microbiology and pharmaceutics result in the
daily discoveries of new and life-saving active pharmaceutical ingredients (APIs). Never-
theless, most people in the developed and developing countries must still fight against a
variety of serious health problems. There may be a host of recognized and unrecognized
5
Figure 1.1 The portions of Gross Domestic Products spent on health care in some coun-
tries.
reasons that could explain such a situation. For example, the doughnut hole gap is widely
referred to as a major problem in existing healthcare systems of some developed countries.
From a chemical and pharmaceutical engineering standpoint, the best solution to narrow
such gap is to manufacture the pharmaceutical products at lowest costs so that more and
more patients in need can afford medicines. It may also be the best way to minimize the
use of expensive APIs most of which are currently protected under patent. In other word,
new drug delivery system should be designed to maximize the efficacy and bioavailability
of APIs.
In the United States, the government has recently decided to reform its healthcare
system in order to minimize the doughnut hole gap. As a result, the demands of pharma-
ceutical products will be dramatically increased. In addition, most blockbuster APIs are
6
Figure 1.2 Life expectations at birth and healthy life expectations at birth in some coun-
tries.
going to be off-patent in a near future. Then, a large amount of cheap generic drugs will
be flooded into the pharmaceutical markets. The effects of those phenomena are expected
not to be limited to the market expansion of the United States. Indeed, many international
big and small pharmaceutical companies are responding to the trends. They understand that
the development of new dosage forms and formulations are the most competent alternatives
of off-patent APIs against generic drugs because the discoveries of new APIs take longer
times than the development of new delivery systems. For example, oral transmucosal fen-
tanyl citrate delivery through an orally dissolving film (ODF) is developed by NAL Pharma
Ltd. This product will compete with Actiq® (Cephalon Inc.) which also releases fentanyl
citrate from lozenge through oral mucosa. Compared to traditional tablets, both products
deliver the API much faster, with higher bioavailability (∼ 0.32 orally; ∼ 0.52 transmucos-
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ally) and more conveniently, i.e., they do not require water when administering.
1.3 Roles of Mathematical Models in Drug Delivery System
Pharmacokinetics and pharmacodynamics (PK/PD) are important areas of pharmaceutical
engineering [13]. The pharmacokinetics is the study that reveals the mechanisms and the
speed of drug transport from the device to systemic circulation, while pharmacodynamics
helps to identify the extent of therapeutic effect as a function of the serum concentration
[14]. Although the mathematical modeling is used in both studies in drug delivery, this
dissertation deals with the pharmacokinetics.
When a new drug delivery device is invented, a series of clinical experiments are
conducted to estimate the various pharmacokinetic parameters: maximum serum concen-
tration, time to reach the maximum concentration and area under curve of concentration vs.
time [15]. The dosage regimen is determined based on those parameters. Clinical exper-
iments require very special cautions: the scientists should not violate numerous rules for
human rights of subjects, the placebo effect of drug should be controlled as well as the inter-
individual variability of pharmacokinetic parameters [16]. Consequently, the costs of the
clinical studies are limitlessly high, and pharmaceutical companies have to cope with such
budgetary loads. The burden is much more increased and the development time is getting
even longer when companies seek to produce a new device for customized drug delivery
based only on laboratory data gathered from patients. In addition, the tremendous number
of clinical tests should be performed under carefully controlled protocols. For example,
the pharmacokinetic studies performed so far have averaged the results over all subjects.
In the development of the customized devices, subjects who have similar pharmacokinetics
should be grouped for averaging, and then the clinical tests are conducted for each group.
A good mathematical model can help researchers reduce costs and production time
by adding in silico experiments to their database (i.e., filling the gaps between laboratory
experiments) and extrapolating to unexplored cases. The detailed procedure is as follows.
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The mathematical models are composed primarily of the differential equations describing
mass conservation in a domain to be analyzed (Chapters 2, 3 and 4). Depending on the
delivery platform, additional equations representing the conservations of energy (Chapter
3) and/or momentum (Chapter 4) may be involved. The solutions of these governing equa-
tions, with appropriate boundary conditions and available parameter values, provide the
concentration profiles within the domain. This result is used to estimate the absorption
rate of drug into the systemic circulation. It can be further implemented to predict serum
concentration change from which the maximum concentration, time to reach the maximum
concentration and the area under curve are calculated. The existences of the analytical so-
lutions depend on the governing equations or the model reduction capabilities of process
engineers. In early times, an asymptotic solution to a specific problem was preferably pur-
sued due to the limited computer resources. Nowadays, on the contrary, nonlinear partial
differential equations, resulting from the combined effects of drug delivery mechanisms
on the release profile, are often solved by numerical methods. Recent advances in digital
computing technology have allowed the efficient solution of such complex problems.
CHAPTER 2
OPTIMAL DRUG DOSAGE REGIMEN
In Chapter 2, the optimization of intravenous drug dosage regimens was investigated based
on a two-compartment pharmacokinetic model. Two dosage forms were considered for
the intravenous administration of the modeled drug, theophylline: intravenous bolus and
infusion. The advantage of bolus dosage form is that it increases plasma drug concentration
promptly, whereas steady intake of drug is achieved by infusion. In clinical therapy, drug is
administered as intravenous bolus injections followed by continuous infusion to minimize
the time required for the pharmaceutical agent to produce a desired therapeutic effect. This
work aims at providing patients with the quickest and safest therapy by properly calculating
the administering amount and time of each dosage.
2.1 Problem Statements
An intravenous (i.v.) infusion treatment has been applied to maintain plasma drug concen-
tration within a prescribed range in a long-term therapy. However, in the beginning of a
treatment, patients may experience discomfort or pain before the drug, supplied to blood
stream, reaches and remains at a therapeutic concentration. In cases where immediate pain
management is necessary, this dead time is not desirable and it should be curtailed. This
challenge has long been addressed by researchers. Mitenko and Ogilvie [17] conducted
clinical experiments in which subjects were administered 61.2 mg of theophylline per
minute in a well-controlled environment. Blood samples were collected at specific times
and analyzed. The data were fit to a two-compartment model in order to estimate pharma-
cokinetic parameters, such as first-order drug elimination and inter-compartmental distri-
bution rate constants. Wagner [18] conducted computer simulations with two-compartment
model using two different infusion-rate administration protocols. The parameters obtained
9
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from [17] were used.
A bolus form of administration usually releases drug instantaneously leading to a
fast increase in a plasma drug concentration whereas a continuous infusion supplies drug
to body at a steady rate. Therefore, in the latter case, a sustained drug level can be achieved
by mitigating the effects of metabolism and elimination. Depending on the application, bo-
lus injections may not provide the best option because frequent dosages are often required
for an effective treatment. Infusion administrations also suffer from a major drawback in
that it takes a long time for the drug to be within a therapeutic range. Therefore, a com-
bined protocol, consisting of multiple boluses prior to infusion, was proposed in [17] to
achieve both fast and efficacious results. In this hybrid system, it is important to keep the
blood concentration within a therapeutic range because, if the concentration is less than
the minimum level, the benefits of the drug will not be observed. Above a minimum toxic
concentration, serious side effects may occur. In order to guarantee safety and effective-
ness of the treatment, clinicians must select appropriate bolus injection schedules, dosage
sizes and infusion rates very carefully. The general optimization methodology developed
by Wheeler and Sheiner [19] helps researchers determine dosage regimens that agree with
the criteria described above. The influence of the infusion rate, with and without initial i.v.
boluses, on the plasma drug concentrations was investigated in a simulation study [19]. The
results helped to assess the effectiveness of several regimens by comparing the minimum
deviations from a desired blood concentration (i.e., mean-square error). According to their
findings, an increase in the number of i.v. boluses led to an increase in the performance,
as measured by the mean-square error between desired and estimated drug concentrations.
The study suggests that a patient should be given a large number of i.v. boluses, which is
impractical due to compliance issues. Besides, their strategy did not take into consideration
the times at which bolus injections are administered. Also, a finite-difference method was
employed to solve the governing differential equations. More efficient numerical computa-
tional methods are available.
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In this study, orthogonal collocation on finite elements (OCFE) techniques and re-
gression algorithms were applied to find the most effective and safe administration method
based on a least mean-square error. Both the dosage times and sizes were considered in
this investigation. Note that the orthogonal collocation method is known to give more ac-
curate and effective computations than a finite-difference discretization [20, 21]. Since the
end-user may be clinicians and healthcare providers, with limited knowledge of mathemat-
ical physiology and computer programming, programs were developed and packaged as
user-friendly add-ons that took multiple inputs (pharmacokinetic parameters and dosage
regimen) and then produced a single output (i.e., an-square error).
A two-compartment pharmacokinetic model is used to elucidate the delivery mech-
anism of drug into body, see Figure 2.1. The human body is modeled as two compartments:
blood as Compartment I (sometimes it is called as serum or quickly perfused tissues) and
peripheral tissues as Compartment II (or slowly perfused tissues). The masses are ex-
pressed as y1 for Compartment I and y2 for Compartment II. The medicament is exchanged
between the two vessels following first-order kinetics; k1 and k2 represent forward and
backward rate constants, respectively. Drug elimination is assumed to take place only in
Compartment I since this process occurs at a much smaller scale in peripheral tissues (e.g.,
fats). Renal clearance in the bladder, metabolic degradation by microbiology and chemical
reaction with other species are examples of potential drug removal processes [22]. The
clearance kinetics, E(t), associated with the different modes shows high nonlinearity with
respect to the plasma drug mass, e.g., Michaelis-Menten kinetics for metabolic degrada-
tion. In this case, an analytical approach may not be possible and numerical solution is a
viable option. If the elimination kinetics is given as a linear function of mass, e.g., only re-
nal clearance occurs, analytical approaches are available. This study examines both cases.
The size of bolus dosage is denoted as Mb; Ri is the constant infusion rate.
The use of two compartments provides more accurate predictions of drug transport















Figure 2.1 Two-compartment pharmacokinetic model with a hybrid dosage form (bolus
plus infusion).
would capture nonlinear trends better than a small number of compartments because the
solution of N-compartment model shows N-manifolds, i.e., N eigenvalues, which agrees
with experimental results. Levitt and Levittąŕs clinical experiments demonstrate the multi-
modal behavior of declining concentration of ethanol after cessation of a long-time steady-
rate infusion. On the other hand, a large number of compartments causes an increase in
the number of parameters to be recovered and, consequently, enhances the problem com-
plexity. Most clinical research employs up to two compartments for the estimation of the
parameters.
2.2 Mathematical Formulations









= k1y1 − k2y2 (2.2)
When N boluses are administered, followed by a constant-rate infusion, the therapeutic
period is divided into N subperiods. Before treatment begins, both compartments are drug-
free. The first bolus is injected at t = 0; the initial mass corresponding to the first subperiod
is the initial dosage size. The initial mass of the j-th subperiod is calculated by adding
the j-th dosage size to the final masses of the (j-1)-th subperiod. Since i.v. boluses are
directly injected in Compartment I, a jump is observed in the drug mass in Compartment
I at the interface of adjacent subperiods. This behavior is not noticed in Compartment II.







0 t < tN
Ri0 t ≥ tN
(2.3)
where tN is the initial time of the last (N-th) subperiod, and Ri0 is a constant infusion rate.
The steady-state masses, y1,ss and y2,ss, are determined by solving the equations obtained
by setting all time derivatives in Equations (2.1) and (2.2) equal to zero. For instance, the
following equation must hold at steady state:
E (t) = Ri (t) (2.4)
According to the nonlinearity of the elimination rate E(t), Equations (2.1) and (2.2) are
solved differently. In this research, two case studies were investigated.
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2.2.1 Elimination Rate Proportional to Mass in Compartment I
In the case where the elimination kinetics is expressed as
E (t) = kEy1 (2.5)
Equation (2.1) is reduced to a linear first-order ODE such that
dy1
dt
=− (k1 − kE)y1 + k2y2 +Ri (t) (2.6)
































































where y1,0 and y2,0 are the initial masses of Compartments I and II, respectively, and the
Greek letters are defined as α = k1 + k2 + kE + δ ; β = k1 + k2 + kE − δ ; γ = k1 − k2 +
kE − δ ; δ =
√
(k1 + k2 + kE)
2−4k2kE ; ε = k1 + k2 − kE + δ ; φ = k1 − k2 + kE + δ and
η = k1 + k2 − kE −δ . Since (k1 + k2 + kE)
2 −4k2kE > 0 and thus δ is real, no oscillation
in concentration is observed.
Suppose that N boluses, of sizes Mb1, Mb2, ..., MbN , are injected at time points
t1(=0), t2, ..., tN prior to infusion, the number of subperiods is also N: the equations for the
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first (N-1) subperiods are obtained by setting Ri (t) = 0; and the equation for the last one
is derived by setting Ri (t) = Ri0. Consequently, the steady-state masses of Compartments










, respectively. The initial
masses are yI
1,0 = Mb1 and y
I
2,0 = 0 for the first subperiod. The superscript number stands
for the subperiod. At t = t2 +0






































where 0− stands for the infinitesimal amount from the negative direction. Similarly, the
































































































































































2.2.2 Elimination Rate Following Michaelis-Menten Kinetics
In this research, it is assumed that drug is administered directly to the systemic circulation
(represented as Compartment I) without any delay caused by various types of biological
barriers. Hence, the first pass metabolism is not considered. However, once a medicament
is introduced into the systemic circulation, it undergoes degradation by a host of biochemi-
cal reactions [23]. The magnitudes of those two mechanisms affect the apparent kinetics of
the overall metabolism. This section focuses specially on drugs subject to biodegradation
by enzymes. The drug loss by chemical reactions with other blood components is con-
sidered less significant in the process. The Michaelis-Menten kinetics is often adopted to






where Vmax is the maximum rate and KM is the Michaelis-Menten constant.
As in the previous case study where a linear-elimination kinetics was assumed, the
constantly administered drug by infusion should be consumed by metabolic degradation
in order to keep drug level in body steady. In other words, the infusion rate is obtained
by setting Equations (2.1) and (2.2) with Equation (2.15) equal to zero at y1 = y1,ss and





The analytical solutions of Equations (2.1) and (2.2) do not exist because of the nonlinearity
of Equation (2.15), and a numerical method is required. However, the linearized system
of Equations (2.1) and (2.2) about the steady state is still able to provide stability analysis
[24]. The trace and the determinant of the Jacobian matrix of Equations (2.1) and (2.2)
with Equation (2.15) are:











respectively. The signs of those two parameters indicate that the steady state, i.e., fixed
point in nonlinear dynamics, is a stable node, minimizing an accidental overdose or an
insufficient dose administered to the patient.
Numerical solutions of Equations (2.1) and (2.2) with Equation (2.15) are pursued
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by using the orthogonal collocations on finite element method. The integrations of those
equations are carried out up to the treatment time, tF . This time span is divided into N
subperiods according to the administration times of N boluses, i.e., t1(=0), t2, ..., tN . One
subperiod is occupied by one finite element and, hence, there are N finite elements. In
a collocation method, a domain, one finite element in OCFE, is rescaled to the range of
0 to 1. The collocation points are assigned according to the roots of Jacobi polynomials.
Collocation method implements all these points to represent derivatives at one position,
which improves accuracy with less computational load. Jumps are introduced between
adjacent finite elements to represent corresponding concentration rises caused by bolus
doses. Mathematica® (Wolfram Research, Inc.) provides the encoding platform best for
concise programming of such a numerical procedure.
2.3 Optimal Dosage Regimens
The optimal dosage of a drug maximizes the efficacy and the safety of the therapy by main-
taining the amount of drug in the body closest to the desired level. By using multiple bo-
luses followed by infusion, the amount of drug in the body can remain as close as possible
to the desired level. However, the frequent bolus doses may cause undesirable situations in
clinical therapy such as severe injection pains. The model implemented in this study does
not take those side-effects into account. Therefore, the number of the bolus injections, N,
must depend entirely on the healthcare providersąŕ determination. Consequently, the de-
sign of the best dosage regimen focuses on the proper choice of the administration times of
the bolus injections, ti(i= 1, 2, ..., N), and the dosage sizes, Mb j (i= 1, 2, ..., N).
In the optimization, the times and the dosage sizes that lead to the minimum devia-
tion of the mass in Compartment I from the desired level, yset , are sought. The deviation is


























where tN+1 is the total period of therapy, tF . Three modules programmed by the author
using Mathematica®: prmts#.mx, objectfn.mx, and Optimizer.nb are required to generate
an optimal regimen. A set of the orthogonally collocated points over the normalized do-
main, 0 to 1, and weights for the Gaussian quadrature integration are defined in prmts#.mx.
The # is the number of internal collocation points, and total number of collocation points
is #+2 including the points at both boundaries. The extension “.mx” stands for a mod-
ule coded as a Mathematica® Package as opposed to “.nb” as a script. By evaluating the
module objectfn.mx with a suggested dosage regimen (function input) after prmts#.mx is
run, the mass profiles in both compartments are calculated. The value of the object func-
tion, Equation (2.19), is also evaluated and returned (function output) to a calling function
which implements an optimization procedure (Optimizer.nb). Once the number of boluses,
duration of treatment, and desired level of theophylline are provided by users, the program
automatically calculate the optimal dosage regimen.
2.3.1 Elimination Rate Proportional to Mass in Compartment I
In this case study, the analytical expression of Equation (2.19) is available because the
closed-form solution for the mass of drug in Compartment I is given in Equation (2.13).




































































































































































































































































Therefore, the deviation defined in Equation (2.19) is obtained by taking a square root on
the summation of Equation (2.20) from j=1 to N and dividing it by tFyset .
The model constructed in this case study has been used to provide an optimal de-
sign of dosage regimen with the drug theophylline. Theophylline is used as a medicament
against asthma, and the therapeutic range is known as 10-20 µg/mL [25]. Serious side-
effects are reported when an accidental overdose occurs: symptoms such as nausea, vomit-
ing and hypokalaemia with more than 25 µg/mL [25]; convulsions are apparent with more
than 50 µg/mL [26]. The desired concentration of theophylline was set to 10 µg/mL, in ac-
cordance with several contributions [17, 18, 25]. This relatively low setting may result in a
period of subtherapeutic drug amount in Compartment I before constant-infusion treatment
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begins. However, it prevents the serious side effects from occurring and reduces the con-
sumption of the expensive theophylline. The pharmacokinetic parameters of theophylline
are reported by Wagner [18]: k1 = 2.73h
−1, k2 = 3.11h
−1, and kE = 0.321h
−1. According
to an apparent distribution volume of 0.277 L/kg, the desired level in mass, yset, and the
maximum therapeutic limit are set at 193.9 mg and 387.8 mg for an average body weight
70.0 kg. From Equation (2.5), the infusion rate is directly calculated as 60.5 mg/h.
A computer program, which evaluates Equations (2.19) and (2.20), and searches for
the best dosage regimen, has been developed with Mathematica® (Wolfram Research, Inc.).
Note that the constraint, such that the first dosage size does not exceed the maximum limit,
is sufficient to guarantee that mass of Compartment I does not exceed the limit during the
entire therapy because of the nature of the system represented by Equations (2.2) and (2.6):
the mass of Compartment I always decreases right after a bolus injection and the mass
of Compartment II does not exceed that of Compartment I. The regimens with 3 and 6
boluses have been tested for 3 hours of therapeutic period, and the results are presented in
Figures 2.2 and 2.3. According to the optimization for 3-bolus treatment, the first bolus
size was 241.74 mg followed by the second one of 74.8 mg in 10.1 minutes, and the third of
63.5 mg in 24.3 minutes. These dosage sizes are represented as three jumps of the mass of
Compartment I (solid line) observed in Figure 2.2. After each jump, the mass of drug in the
blood (Compartment I) declines due to distribution to the perfused tissues and elimination.
With this regimen, the deviation, Equation (2.19), was estimated at 0.0309. It is worth
noting that a small offset in the mass of Compartment I is observed in the third subperiod
where a constant infusion is applied. However, the system represented by Equations (2.2)
and (2.6) is stable at the fixed point, i.e., the desired level, and thus the mass is approaching
the equilibrium value. When 6 bolus injections are used prior to the constant-rate infusion,
the deviation, Equation (2.19), is improved up to 0.0174, and a much smaller offset is
observed because of frequent doses of small amounts: the first of 218.6 mg; 43.2 mg at
5.1 min.; 39.6 mg at 11.2 min.; 35.9 mg at 18.5 min.; 32.3 mg at 27.5 min.; 29.3 mg at
22
38.7 min. Comparing the results of 3- and 6-boluses regimens, it is evident that more bolus
administration lead to better performance or less deviation. Nevertheless, clinicians must
pay careful attention to the prescriptions considering the unpleasant side-effects such as



















Figure 2.2 The time courses of masses of theophylline in Compartments I and II with the
linear elimination rate model when the optimized 3-bolus/infusion regimen is applied.
The estimation of plasma drug mass profile in a post-therapy period is as impor-
tant as knowing the amount of drug in the blood at any time because follow-up treatments,
using the same or a different drug, must take into consideration the recently administered
medications. Otherwise, another treatment applied before all theophylline disappears in the
body may cause accidental overdose due to the underestimation of the initial drug content.
In addition, undesired chemical reactions can occur when other drugs are administered
in the presence of theophylline. These reactions may produce side-products that can act
as poisons, or, at least, lessen the drug amount in the body, resulting in a sub-optimum
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Figure 2.3 The time courses of masses of theophylline in Compartment I and II with the
linear elimination model when the optimized 6-bolus/infusion regimen is applied.
Equations (2.1) and (2.2) until the mass in each compartment drops to an insignificant
level. Alternatively, the decreasing mass of theophylline, at the end of the treatment, may
be approximated by a first order exponential decay. This approach is valid only when drug
elimination is the rate limiting mechanism. That is, the elimination rate is much smaller
than the inter-compartmental distribution, and thus the masses of drug in both compart-
ments are kept in equilibrium. Then, the mass in the blood, y1, is expressed as:
y1 = 10exp(−kEt) . (2.21)













According to Equation (2.22), it is not recommended to begin another treatment with theo-
phylline or any other drug that is suspected to react with theophylline unless a period of
time equal to t99 (14.7 hours with kE=0.312 h
−1) has elapsed after the treatment ends.
The computer program is able to estimate optimized dosage regimen of different
medicaments and for individual patients. For public access, this procedure is posted on the
web <http://webmath.njit.edu/webMathematica/mathsimon/compartment2.jsp> powered by
webMathematica® (Wolfram Research, Inc.). Hence, no mathematical or computational
expertise is required to run the program. Once a user enters the pharmacokinetic data for a
medicament, the optimal dosage schedule will be calculated. As noticed, it is still necessary
to provide pharmacokinetic information in this first version of the program. In the future,
collaborations with the other researchers around the world will lead to the development of
the ready-to-use library of the pharmacokinetic data for a number of drugs. In this case,
only the name of medication will be sufficient for estimating optimum dosage protocols.
2.3.2 Elimination Rate Following Michaelis-Menten Kinetics
The nonlinear Michaelis-Menten kinetic model of the drug, theophylline, was implemented
by Ishizaki and Kubo [27] to explore the metabolic elimination. In a clinical experiment,
the subjects consisted of 49 children and 21 adults. The kinetic parameters, Vmax and KM ,
recovered from the experiments vary from individual to individual. The average values are
Vmax=81.67 mg/h and KM=467.3 mg. From Equation (2.16) and the desired level 193.9 mg,
these average values lead to the constant infusion rate of 23.95 mg/h. For other parameters,
the values that were used in the first case study were employed again.
The numerical strategy described in Section 2.2.2 and the object function, Equa-
tion (2.19), resulted in the optimal dosage regimen of three boluses followed by a constant
infusion: the first bolus of size 240.8 mg; the second of 71.7 at 10.8 min; and the last of
58.4 mg at 27.6 min. The infusion therapy starts with the last bolus. The number of the
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collocation points per finite element is 9, and the value of Equation (2.19) is 0.02948. With
the obtained regimen, the time courses of the masses in both compartments are plotted in
Figure 2.4. It is worth noting that a total 13 collocation points are used to better represent
the amounts of drug in both compartments (Figure 2.4). The blank squares and circles stand
for the collocation points. In this case, the value of Equation (2.19) is calculated at 0.02948
which is exactly the same as that calculated with 9 points. This shows the advantage of
the orthogonal collocation method in solving differential equations as opposed to the finite
difference method. For example, a total of 27 (actually 21 because the integrations are not
performed for the outer two points) collocation points can provide an accurate solution for
the domain of size 3, whereas a set of 30 evenly-spaced points, i.e., the size of finite differ-
ence is 0.1, would be a good usual starting in a finite difference method. The allocation of
different number of collocation points on different finite element can also be implemented
to reduce the computational load. As illustrated in Figure 2.4, the sizes of the first two
finite elements, i.e., time spans from the first to second bolus and from the second to third
ones, are relatively smaller than the last one, i.e., from the third bolus to the end of therapy.
This is also observed in different systems regardless of the kinetic properties and number of
boluses. It is well-known that a simulation of the system that has smaller domain requires
less number of discretization points. Hence, the use of less collocation points is possible in
the solutions for the first two subperiods, but it will not be demonstrated in this research.
Physiological properties, such as the drug distribution rates, elimination capacity,
and volume of distribution, depend entirely on the individual patient: types of drugs that
are being co-administered, gender, age, health (disease history) and diet. Hence, setting
up a new dosage schedule of the prescribed drug requires running the programs that are
developed in this research with the knowledge of the patient-specific pharmacokinetic in-
formation. However, unlike the first case study in which an analytical solution is avail-
able, the optimization of the dosage regimen requires extensive computational time, e.g.,






























































Figure 2.4 Time courses of masses of theophylline in Compartment I and II with the
Michaelis-Menten elimination kinetics when the optimized 3-bolus-infusion regimen is
used.
spite of the advantages of the OCFE approach and a high-performance computer. These
time-consuming computations may not be acceptable to the potential users (clinicians and
patients) even though the results are likely to lead to safe and efficient drug administra-
tion protocols. To circumvent this problem, best dosage regimens corresponding to spe-
cific pharmacokinetic parameters are pre-calculated and used to quickly estimate unknown
doses and administration times for patients by interpolation (Table 2.1). The ten rows in
Table 2-1 are generated as follows: the first row indicates the optimal dosage regimen at the
nominal values of the pharmacokinetic parameters (i.e., Figure 2.4); the second and third
ones show the regimen when the value of k1 changes to 150 % and 50 % of the nominal
value, respectively, with others remaining constant; the same variations are applied to k2
in the fourth and fifth rows, to Vmax in the sixth and seventh, and to KM in the eighth and
ninth. The last row of Table 2.1 uses interpolation based on the results of the first nine
rows. For the test, k1 is increased by 20 % of its nominal value while Vmax and KM are de-
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creased by 20 % of their nominal values; k2 remains unchanged. Linear regression and the
optimization procedure described in this work (numbers in parenthesis) give similar results
(Table 2.1). As a result, interpolation can be used to decide the administration times and
dosages necessary to keep the plasma drug concentration at a desired level. It is worth not-
ing that the estimation by a linear regression takes a thousandth of a second while showing
close agreement with the results of the full-scheme optimization. This approach may allow
researchers to fill a table, similar to Table 2.1, for different medicaments, which will reduce
the time to market of drugs and avoid the collection of additional blood sample data from
individual patients.
Table 2.1 Optimal Dosage Regimens with Different Values of Pharmacokinetic Parameters
k1 k2 Vmax KM
Initial
Second Dosage Third Dosage
Infusion
Dosage Rate
[1/hr] [1/hr] [mg/h] [mg]
Size Size Time Size Time
[mg/hr]
[mg] [mg] [min] [mg] [min]
2.73 3.11 81.67 467.3 240.8 71.7 10.8 58.4 27.6 24.0
4.09 3.11 81.67 467.3 263.1 102.8 10.2 86.3 25.8 24.0
1.36 3.11 81.67 467.3 218.1 38.8 11.4 31.4 28.2 24.0
2.73 4.67 81.67 467.3 225.3 48.9 7.8 39.4 19.2 24.0
2.73 1.56 81.67 467.3 283.9 132.0 18.6 112.5 46.2 24.0
2.73 3.11 122.51 467.3 241.6 73.1 10.8 60.9 26.4 35.9
2.73 3.11 40.84 467.3 240.2 70.2 10.8 55.6 28.8 12.0
2.73 3.11 81.67 700.95 240.4 71.0 10.8 57.0 28.2 17.7
2.73 3.11 81.67 233.65 241.6 73.3 10.8 61.1 26.4 37.0
3.27 3.11 65.34 373.84
249.5 83.8 10.8 68.3 27.6
22.3
(249.5) (83.5) (10.6) (68.4) (27.4)
2.3.3 Other Case Studies
The strategy developed in this contribution can be applied to prescribe drugs with pharma-
cokinetics different from theophylline. For example, the Michaelis-Menten kinetics, the
values of Vmax and KM , of ethanol, as an anesthetic agent, have been reported by other
researchers [28, 29]. Transdermal drug delivery can be considered in the context of two-
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compartment model in the presence of drug metabolisms in skin layers [30]. The strategy
outlined can also be used to design drug dosage regimens that are based on time-dependent
pharmacokinetic parameters. In this case, the drug kinetics needs to be well- formulated as
a function of time. The approach is relevant to patients with chronic diseases whose treat-
ment times are relatively long so that the body conditions are expected to change during
the therapy. For example, experiments performed by Saadeddin et. al. show changes in the
clearance rate of all-trans-retinoic acid (ARTA) occur at 180 min after an intravenous bolus
injection [31]. As time elapses, the plasma drug concentrations shows an exponential decay
followed by a linear decrease, after reaching a plateau, due to an increase in the elimination
rate constant. Based on these observations, the elimination rate constant was expressed as
a function of time [31]. This problem can be addressed in the present framework.
2.4 Conclusions
In this study, a two-compartment pharmacokinetic model was implemented to estimate
optimal dosage regimens consisting of multiple intravenous boluses and a constant-rate
infusion administration. Two different kinetic mechanisms for the theophylline elimina-
tion were used: linear and Michaelis-Menten metabolisms. Programs were written in a
Mathematica® platform in order to estimate the administration time, dose sizes and infu-
sion rate once the user inputs the number of boluses, treatment time and the desired mass of
drug in the body. This contribution is posted on the Online Laboratory <http://webmath.njit
.edu/webMathematica/mathsimon/compartment2.jsp>. Users can access and run the op-
timization program with minimum knowledge of mathematics, engineering or computer
programming. Further versions of this program, developed in collaboration with clini-
cians, will include a library of pharmacokinetic parameters for a list of drugs. The creation
of a platform that simulates plasma drug concentrations and calculates optimum dosage
regimen will facilitate the development of safe and efficacious therapeutic strategies.
CHAPTER 3
HEAT-AIDED TRANSDERMAL DRUG DELIVERY
Transdermal drug delivery refers to a method of administration in which a therapeutic dose
of medicine enters the systemic circulation through layers in skin. During the journey of
drug to the systemic circulation through this dermal route, drugs do not undergo first-pass
metabolism which is one of the biggest challenges in oral administration of medications.
A patch is a sheet of drug-containing polymer, and is the most commonly consumed trans-
dermal delivery device. By contacting with skin, it can provide continuous and steady
dose of drug during a therapy: testosterone (Androderm®), sestrogen and progestogen
(Ortho-Evra®), easing cigarette cravings (Nicoderm CQ®), and relieving motion sickness
(Transderm-Scop®). This device can replace disposable hypodermal needle and minimize
risks of infections and other diseases due to the reuse of the needles. In addition, the trans-
dermal delivery device is usually placed outside the patient body during therapy. This way,
the user is granted full access to the product so that quick changes in operational conditions
can be made. Consequently, tighter control of drug release can be achieved by using the
transdermal products compared to other types of delivery systems (e.g., implants or pills).
Nevertheless, low permeability of drug through skin imposes significant limitations
to existing transdermal drug delivery technologies such as inevitable initial delay of drug
release [32] and slow therapeutic effect. Stratum corneum is the outermost layer of skin
that is composed of dry and dead cells. Although it is much thinner than other layers,
it plays a great role in blocking drug passage to body. Therefore, continuous efforts to
accelerate the delivery of drug through skin have been made by using chemical (e.g. water,
oleic acid, and acetone) and physical enhancers (e.g. electric current, ultrasound, magnetic
field, and heat). The chemical enhancers are applied on skin before patch and activate
transport mechanism by widening openings in the stratum corneum. Chemicals for this
purpose should not be expensive, harmful on skin, and must be used properly to prevent
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side-effect such as skin irritation [33]. The release control in use of chemical enhancers
depends largely on physical properties and application forms of the materials.
Iontophoresis [34, 35] uses mild electric current to force ionized or charged drugs
through the stratum corneum. In sonophoresis, low-frequency ultrasounds are used to dis-
turb lipid bilayers [36, 37, 38]. In these applications, precise and easy control of drug deliv-
ery rate can be achieved because patientąŕs requirement is almost instantaneously reflected
to modules by microprocessors and electric signals. By the way, use of such electronics
may increase volume and cost of product (note that the cheapest microprocessors are usu-
ally more expensive than a bundle of patches). This causes poor patientąŕs compliance and
affordability. Especially, physically-challenged patients have difficulty to carry with big
and heavy devices.
The enhancing medium employed in this research is heat from outside a patch.
Elevated temperatures of patch and skin due to applied heat result in increased diffusions
through the layers. Control of heat and, consequently, drug delivery is highly required since
excessive heat causes thermal injury of skin (burn) and accidental overdose. Instead of
heavy electronic, heat is available from a thin, light-weighted and, moreover, cheap heating
pad where an exothermic reaction takes place. However, control protocol of drug release
should be carefully prepared prior to taking such advantages. In this context, the point of
this investigation is to understand the influence of applied heat on controlled release of drug
through transdermal drug delivery and to know the role of mathematical model in detailed
design of the heat-aided transdermal delivery device.
3.1 Problem Statements
Patch is the most popular transdermal delivery device due to its convenience. A sheet of
patch is mainly composed of three layers: backing material, drug-loaded polymer, and
adhesives. The backing material prevents loss of active pharmaceutical ingredients (API)
blended in the polymer. On the opposite side, the adhesive helps to affix the patch to the
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patientąŕs skin. It forms another layer between the drug-loaded polymer and the skin but
also acts as a barrier to the drug delivery. In recent products, self-adhesive polymers are
commonly adopted so that diffusion resistance through this region can be effectively ig-
nored compared to transport in the drug-loaded polymer or in the skin. Consequently, a
mathematical representation of the transport phenomena does not consider the presence of
the adhesive. Once the patch is worn on the skin, the API and other materials begin to move
by passive diffusion toward the depth of the skin until they are absorbed to the systemic
circulation. The skin is composed of different physiological layers: stratum corneum, epi-
dermis, dermis and others. The layers exhibit different transport properties. In practice,
a single-layer model, with uniform properties, is usually implemented to simulate drug
transport through the skin.
In this work, a sheet of heating pad is placed in the backing material in order to pro-
mote release of the medicine. The heat released from the pad increases the temperatures of
the patch and the skin which leads to increases in drug diffusivities in those layers (active
diffusion). Hence, controlled release of the drug can be achieved by manipulating the de-
sign parameters of the heating pad. The heating pad, modeled in this research, is composed
of powder mixture of iron as solid reactant, charcoal, salt and moisture as catalyses, and
vermiculite as insulator. Those materials are packed by an air-permeable pouching mate-
rial. The shape of the pad is similar to that of the patch: an adhesive helps to affix the pad
to the backing material on one side; an air-tight seal is attached on the other side. Once the
seal is removed, oxygen begins to penetrate into the pouch and an exothermic oxidation
of iron takes place. Other materials in the heating pad do not participate in the reaction
but are still important because they determine thermal characteristics, such as overall heat
capacity. These components also initiate and promote the exothermic reaction. Two design
parameters are associated with the use of the heating pad: the maximum temperature and
the duration of the pad application. Because the human skin is composed of viable pro-
teins, excessive heat may result in irritation, redness, shock and/or burn. It is reported that
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exposure to a heating pad producing more than 55 ◦Ccan cause a serious thermal injury
[39]. In light of this, clinical experiments have focused on a maximum skin temperature
of 55 ◦C. In practice, several applications of the pad may be required for effective ther-
apy due to the time it takes the constituents to completely react. In fact, the reaction in a
pad does not last more than 6 hours while the temperature of the system starts decreasing
before that time. With a patch, such as Duragesic®, which is applied for more than 36
hours, the delivery enhancement is observed only at the beginning of the treatment. In this
case, multiple applications of the heating pads are more likely to induce enhanced release
of the medicament than a single application. This research deals primarily with the case of
a single application of the heating pad. The findings of this work may be extrapolated to
the repeated application protocol. Also, this strategy is critical in reducing the initial time
lag [40, 41].
The configuration described above is shown in Figure 3.1. Since a patch with a
heating pad usually forms a thin layer, but a wide surface area, on a skin, transverse trans-
ports of heat and drug are only considered. The boundary between the drug loaded polymer
(patch hereafter) and the backing material (back hereafter) lies at x = −LII. The outer sur-
face of the heating pad is at x = −LI so that the thickness of the pad is LI −LII. From a
physiological standpoint, the interface between the skin and the body core is not clearly
defined. Nevertheless, this model places the boundary at LIII , where the capillary vessels
are found and the drug absorption begins. At that position, instantaneous uptake of the drug
(i.e., the perfect sink condition) is assumed.
In Figure 3.2, the expected profiles of temperature (dashed line) and concentration
(solid line) are shown for a better understanding of the system treated in this research.
Since the backing material is impermeable to the drug ingredient, the concentration of
drug in the heating pad is always zero. The instant-drug absorption assumption at the
boundary between skin and body core (see Figure 3.1), leads to the zero concentration at
that position. The discontinuity in the concentration observed at the patch-skin boundary is
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Figure 3.1 Physical configuration of a heat-enhanced transdermal drug delivery protocol.
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due to the equilibrium between two media, which is called partitioning. On the other hand,
the temperature distribution in the pad is considered uniform. No partitioning is observed
and the temperature is continuous at every position. The temperature beyond the skin layer
is not shown, but is kept unchanged far from the patch (at x → ∞). This configuration does
not take the thicknesses of the pouch and backing materials into account.
Max. Temp.
Body Temp.
-LI -LII 0 LIII
x
Initial Conc.




Figure 3.2 Expected temperature and concentration profiles observed throughout the treat-
ment by the transdermal drug delivery protocol used in this research.
The one-dimensional analysis on the transdermal drug delivery configured in Fig-
ure 3.1 is already available in the work done by Kim and Simon [3]. In the previous work,
four design parameters defined by virtue of the mathematical model were implemented to
i) analyze the dynamic transports of heat and drug to the body, ii) explore optimum designs
and sort the relative sensitivity of those parameters to the optimum design. The results led
to the conclusion that the initial concentration of corticosterone in a patch is of most impor-
tance than other factors such as, in a descending order, initial reaction rate of a heating pad,
total mass of the pad, and overall heat transfer coefficient of the patch. However, the model
is constructed under the assumption that the domain of heat transfer is same as that of mass
transfer. Thus, the temperature at the boundary between skin and capillary region was kept
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constant. This represents benefits of the application of heating pad in the diffusion of drug
to the capillary region (body core or systemic circulation), but cannot show any change in
drug absorption. Therefore, modifications in the mathematical model are now required to
maximize the applicability of the suggested heat-enhanced transdermal drug delivery pro-
tocol. First, the domain of the heat transfer is considered semi-infinite (from heating pad
to somewhere in the body). Second, Arrhenius-type diffusivities are adopted as opposed to
the linear model. Those changes allow the mathematical model to be validated using the
experimental results published by [9].
In the following sections, the governing equations and the conditions are derived
and a numerical solution methodology will be outlined. The constructions of those equa-
tions allow the identification of design factors that can affect the release profile. The so-
lutions first provide insights into the dynamics of heat and mass transfers throughout the
therapy and will facilitate qualitative and quantitative studies of the effects of the design
parameters on the release profile. The findings of this contribution will also help in the
fabrication of transdermal drug delivery systems.
3.2 Mathematical Formulations
In drug delivery research, mathematical-modeling study provides a deeper understanding of
phenomena that cannot be observed with naked eyes or detected by sensors. For example,
in the absence of an analytical model, it would be very difficult and expensive to moni-
tor the temperature profile through the skin. In this case, a mathematical representation,
based on mass and energy balances, can be instrumental as it represents the distribution
of concentration and temperature through the skin or much thinner viable membrane. The
process described in Figure 3.1 is translated into a set of mathematical equations that ad-
dress the transport of heat and mass throughout the system in addition to boundary and
initial conditions that refer to external factors influencing the drug delivery. The results of
the mathematical modelings can contribute to the optimal designs of new pharmaceutical
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devices and treatment schedules to specific diseases and patients. A dimensional analysis
of the model can provide the design factors which can later be used in developing guideline
for the best therapy protocol.
3.2.1 Mass and Energy Balances in Heating Pad
The heating pad neither contains any active pharmaceutical ingredient nor contributes to
the therapeutic treatment directly. The role of the pad in this protocol is to provide a
barrier of drug delivery with an extra heat to facilitate the passage of medication to the
systemic circulation. In order to accomplish this purpose, an exothermic chemical reaction
(oxidation of iron) is commonly used such that
4Fe+3O2 → 2Fe2O3 (3.1)
The heterogeneous reaction is initiated by the exposure of the iron powder to the oxygen
in the air. One kilogram of iron is known to release 7436 kJ of heat when it completely
oxidized to iron oxide [42]. It is assumed that only three fifths of this energy contributes to
warm a heating pad up, and the rest is lost to outer environment. Note that the net oxidation
energy is still large so that even slow oxidation may result in an extremely high tempera-
ture of a heating pad. Unless it is controlled properly, the reaction can cause serious injury
such as burned skin. For this reason, the pad also includes charcoal, vermiculite, salt and
sometimes a small amount of moisture. Those filler materials do not affect any thermo-
dynamic properties of the reaction, Equation (3.1). However, those materials increase the
heat capacity of the pad to prevent the temperature from rising sharply. Moisture and salt
act as catalysts of the reaction.
In the case of heterogeneous reaction, two rate-determination steps must be consid-
ered: 1) mass transfer limitation due to the poor mixing oxygen with and the slow move-
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ment of the gas, 2) chemical reaction rate limitation due to the slow reaction rate. In this
work, it is hypothesized that the oxidation of iron powder controls the reaction rate. Since
oxygen is abundant in the air (about 20 %), it is also assumed that its concentration is kept
constant during the process. This consideration leads to two consequences: Consequently,
first, the iron powder is treated as the limiting reactant. Second, the reaction rate is a func-
tion of only the concentration of iron, more specifically, the remaining amount of iron in







where k1 is the rate constant and n is the order of the reaction rate. The rate constant is a
function of only temperature. An Arrhenius-type dependency has been a good candidate in
many non-isothermal reaction kinetics studies [43]. In this drug delivery protocol, however,
it is set constant because the range of the temperature change is too narrow to show a
significant variation. The order of reaction can be only determined only by conducting
experiments. The introduction of the conversion of iron powder, ξ , and the dimensionless








where τ0 is a characteristic time that will be defined later. With an arbitrary choice of n=2,





with A = τ0k1CIron,0. From Equation (3.4), the estimation of the time for the iron powder
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to be exhausted is possible. To write an energy balance for the heating pad, it is worth
















where V is the volume of the pad. The negative sign is used to state the total enthalpy of
the reactants and the products decreases as a result of the exothermic reaction. The heat of
reaction, ∆HR, is a function of temperature such as

























The first bracket of Equation (3.6) is the heat of oxidation of iron at standard condition
(1 atm and TR= 25
◦C) that is obtained from the heats of formation of the reactants and
the product. The second bracket denotes the deviation from the reference temperature, TR.
The heat capacities of the reactants and the product are available as polynomial functions
of temperature. It is worth noticing that the mild change of temperature does not signif-
icantly influence the heat of reaction and the effect can be ignored. For example, a 100
◦Ctemperature difference results in only 1kJ/kg (the first term is 7436 kJ/kg) [42].









+UA(T̄II − T̄I)|x=−LII (3.7)
where m and Ĉp,Iron are the mass and the heat capacity of the pad; U and A are the overall
heat transfer coefficient and the surface area of a backing material of the patch, respectively.
The subscripts I and II denote the heating pad and the patch, respectively. The initial
temperature of the pad is set equal to the body temperature (T0 =37
◦C)
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T̄I (t = 0) = T0 (3.8)
Defining the maximum temperature Tmax as the highest temperature that does not
cause any thermal injury to the viable skin (55 ◦C), dimensionless expression of tempera-





Therefore, dimensionless form of Equation (3.7) is
dTI
dτ
= (1−ξ)2 +B(TII −TI)|ζ=−1 (3.10)
where τ0 is defined as time required for the pad to reach the maximum temperature, Tmax, by










measures the ratio of the rates of heat loss to generation by the reaction. The dimensionless
coordinate is ζ = x
/
LIII . Note that the mass of pad is used instead of the density because
the density of the mixture varies with the composition and the particle size. Then, the initial
condition becomes at τ=0,
TI = 0. (3.11)
40
3.2.2 Mass and Energy Balances in Patch
A common transdermal patch contains a thin film of polymer matrix uniformly blended
with a drug. During the medical treatment, the adhesive side of the patch is in contact with
a small area of bare skin and releases the active pharmaceutical ingredient. The decrease in
the amount of drug results in a concentration gradient and, consequently, the movement of
medication by diffusion. Because diffusivity is an increasing function of temperature, the













where C̄II is the drug concentration in the polymer matrix and DII (T̄II) is the diffusivity
through the polymer matrix as a function of temperature.
The backing material is designed in such a way that it is impermeable to the drug




















where C̄III is the concentration of drug in the skin, and KM is the partition coefficient which







When the heating pad is in contact with the backing material and the air-tight seal
is removed, the temperature in the patch, at the backing material, begins to increase sub-






















T̄II |x=−LII − T̄I
)
. (3.17)
The temperature at the patch-skin boundary is equal to each other:
T̄II |x=0 = T̄III |x=0. (3.18)
The temperature of the patch before treatment begins is kept at body temperature:
T̄II|t=0 = T0. (3.19)
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Following a method similar to the one adopted in the energy balance for the pad,




















CII|ζ=0 = KM CIII|ζ=0, (3.22)





















TII |ζ=0 = TIII |ζ=0, (3.26)
and
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TII |τ=0 = 0. (3.27)
The dimensionless diffusivity is DII =
τ0DII
L2III




and CIII = C̄III
/
C0




The new constant C is defined as C = ULIIIκII .
3.2.3 Mass and Energy Balances in Skin
The transport mechanisms through the skin are similar to those in the patch: drug diffu-
sion and heat conduction. However, the skin contains several different layers with unique
transport properties. For example, the stratum corneum (SC) is the outermost layer of skin
and is composed by dry, dead cells [7]. Although the SC is a very thin layer of skin, it
offers the most resistance to drug penetration when compared to the epidermis and dermis.
Nevertheless, this study proposes a single layer model where the physical properties are
uniform throughout the skin. In spite of the simplicity of the single layer model, it can
provide valuable results that can be incorporated in clinical drug permeation tests because
many of these studies focus on the overall skin instead of the distinct layers. Medication
that is transported to the deep skin is subjected to absorption to the systemic circulation
through the capillary vessels.























































where ρIII and Ĉp,III are the density and heat capacity of skin, respectively. The heat























Far from the surface of skin, it is assumed that the temperature is kept at the body temper-
ature:
T̄III |x→∞ = T0. (3.34)
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Initially, the skin temperature is set equal to the body temperature:
T̄III |t=0 = T0. (3.35)
The perfect sink condition employed in Equation (4.36) allows a simple analysis
on the drug delivery system, although it is valid only when the blood circulation rate is
sufficiently high so that drug concentration in blood can remain very low. This assumption
is made in in-vitro experiments and mathematical simulations [72, 73]. In the case of
insufficient circulation, however, drug will be accumulated around the capillary vessel and
other analysis should be considered [74, 75, 76].
































CIII |ζ=1 = 0, (3.38)




























TIII |ζ→∞ = 0, (3.42)
and
TIII |τ=0 = 0. (3.43)




ratio of the diffusivities at the patch-skin interface is E = DIII
DII
; the dimensionless thermal
diffusivity of skin is αIII =
τ0κIII
L2IIIρIIIĈp,III
and the ratio of thermal conductivities at the patch-
skin interface is F = κIIIκII .
3.2.4 Optimization Protocol
Solutions of the partial differential equations and the boundary and initial conditions, i.e.,
Equations (3.9), (3.10), (3.19) to (3.25) and (3.35) to (3.42), allow researchers to monitor
the following variables: 1) concentrations through patch and skin, 2) temperature of heat-
ing pad, patch and skin, 3) flux of drug to body, 4) cumulative amount of drug, and so forth.
Among them, flux is the most associated factor to rate of drug absorption. After patch is ap-
plied, flux appears four characteristic period: Dormant Period; Exponential Period; Quasi
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Steady Period; and Declining Period. In dormant period, flux is negligible since drug is yet
available at the depth where capillaries are found. Time required for drug to be absorbed
significantly is called “lag time.” In the transdermal drug delivery, the estimation of the
lag time by method of eigenvalue is addressed in the literature [56]. Absorption of drug
begins in exponential period so that flux increases gradually up to a certain level. When
flux reaches maximum, quasi steady period comes. During that period, drug release rate
is subjected to a relatively small change until remaining drug in the patch is not sufficient
to maintain the desired flux. Finally, in declining period, flux decreases steadily until the
remaining amount of drug in the patch and the skin is completely consumed. Based on such
observation, therapy should end before the declining period, and a long-period therapy may
consist of multiple applications of transdermal patches.
The mathematical representation of flux at the end of skin (x = LIII) discussed above
is given by




Due to the elimination of drug by metabolism and renal clearance, this flux should be
maintained at a desired level in order to keep patient within a therapeutic range. Therefore,











where τT is the duration of a treatment with a single patch, and Jset is the desired flux
of drug. The same procedure used in the optimization in Chapter 2 has been followed.
Significant factors that affect flux are determined. Flux and ISE are repeatedly calculated
with randomly or systematically chosen values of those factors until minimum ISE is found.
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3.3 Physical Properties and Design Parameters
The benefits of the mathematical modeling implemented in this research are: 1) the non-
invasive monitoring of drug transport through the patch and skin, 2) the quantitative assess-
ment of the effect of an external heat source on the enhanced drug delivery, 3) the broad
applications of the findings to the controlled release of medications and 4) significant im-
provements in the design of controlled-release devices for various drugs. For the purpose
of simulations and to increase the applicability of the results, information on the physical
properties of drug, pad, patch and skin is required. The related experiments and products
developed for the enhanced drug delivery up to date do not provide all the physical prop-
erties necessary in this study. For example, the temperature dependency of the diffusivity
of a drug in a biomaterial is not published. Because of the complexity in the analysis of
drug transport through the skin, only the overall permeability is measured in most of the
clinical experiments. The results of such experiments are applicable to specific purposes
and products but are not suitable for general designs. Estimation equations are often used
to estimate parameters in the absence of experimental data. The literatures offer empir-
ical diffusivity equations such as Wilke-Chang [44, 45], Tyn-Calus [46] and Chen-Chen
[42] correlations. Although those theories are valid for a range of chemical engineering
processes, they usually involve constraints that make them unsuitable for biosystems. For







Equation (3.46) provides reliable estimation (within 10 % error) for the diffusivity
of very large molecules (MB>1000) in a dilute liquid [42]. But note that drugs such as
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fentanyl or corticosterone have molecular weight of only 200-400 Daltons. In addition,
Equation (3.46) is not a linear function of temperature since viscosity of media, η , also
varies with temperature. Thus, process designers must deal with the viscosities of the for-
mulation medium. It is also impractical to prepare tables for the diffusivities of thousands
of drugs in a large number of possible media for given temperatures. Therefore, in this
research, estimation models will be selected to compute parameters that are not available
in the literature. Although these correlations may not be accurate for the systems used in
the study, the findings, however, can also be applied in controlled-release research to help
identify important design features. The equations can also lead to the development of meth-
ods for extracting key properties. The simulation platform will help researchers reduce the
number of experiments which will to save valuable time and efforts.
In the design of a transdermal drug delivery patch enhanced by an external heat, a
host of parameters affect the release profile, e.g., from the composition of the pad mate-
rial to the thickness of patch. As a result, medical device manufacturers are charged with
the task of carefully selecting among several options, process and design parameters, at
their optimum levels, for a particular application. Not all possible combinations of these
variables are tested in the laboratory. Instead, a few important factors (called “design pa-
rameters hereafter”) are selected and tested to produce a desired therapeutic effect. The
general guidelines for choosing the design parameters are 1) the value of the parameter can
be controlled easily, e.g., simply by changing the material, thickness, composition or size,
2) the parameters are independent of each other, 3) the release profile must be more sensi-
tive to changes in the design parameters compared to the influence of other specifications.
In this context, the results of this investigation can help manufacturers of controlled release
devices develop strategies to identify the design parameters, determine the best combina-
tion and assess the effects of those parameters on the release profile. Such analysis will also
provide the relative importance of the selected design parameters. Further process design
experiments and clinical tests can be performed based on the relative importance measures.
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3.3.1 Material Properties
As a model drug, corticosterone is selected. Corticosterone is a steroid hormone secreted
by the adrenal glands. Steroid hormones, such as corticosterone, play important roles in
the regulation metabolism and affect the immune system and behaviors. Recent studies
found that a prenatal administration of corticosterone to the common lizard results in less
dispersal life style of its juvenile [47, 48]. Other investigation also found that excessive
corticosterone indirectly affects abdominal obesity since it stimulates calorie intake [49].
Hence, the administration of corticosterone requires careful considerations. The results of
this research will contribute to the controlled-release of corticosterone.
The patch is assumed to be made of poly (ethylene-co-vinyl acetate) polymer (so
called EVA polymer). EVA polymer is a good candidate of transdermal patch material since
it has high flexibility and adhesion characteristics at a low temperature. The thickness of
EVA polymer is set to 5× 10−3 m (5 mm). Thermal conductivity [50], density [51], heat
capacity [50] and diffusivity [52] of commonly used EVA polymer are available in the
literature. Based on those values, the thermal diffusivity of EVA polymer is estimated at
5.483× 10−7m2/s. This value is assumed to be constant in the narrow temperature range
of 37-55 ◦C. This choice is supported by publications demonstrating a weak functionality
of thermal diffusivity, e.g., κ ∝ T 0.5 and Cp ∝ T
0.73 [50]. Only the effect of heat on the
drug diffusivity is studied in this contribution.
The partition coefficient is defined as the ratio of the concentrations of a material
(corticosterone) in two immiscible, contiguous media at equilibrium. In pharmaceutical
sciences, the octanol-water partition coefficient is often referred as a measurement of hy-
drophobicity of a drug. Even though the drug delivery model in this study does not de-
scribes the equilibrium system, the boundary condition as Equation (3.14) is valid since
it is assumed that the equilibrium is achieved much faster than the outflow of drug at the
boundary. The reciprocal of the partition coefficient, 1
/
KM , of corticosterone in lipid bi-
layers of stratum corneum is reported as 39 [53].
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3.3.2 Temperature Dependence of Diffusivity
The Arrhenius-type temperature dependence of diffusivity has been used in the analyses
involving the non-isothermal transport of drug through polymeric membranes [43]. In
studies on the moisture loss in heat, a spherical model was implemented and predicted
results were compared with experimental data [54]. The results showed a linear relationship
between the natural logarithm of diffusivity and the reciprocal of the absolute temperature
(Arrhenius-type).
In the absence of the complete set of data for the diffusivities of drug in the EVA
polymer and skin, this research proposes to implement the Arrhenius-type functionality
[40, 43] such that









where D0 is the diffusivity of drug at reference temperature (body temperature, T0, herein),
and Ea is activation energy of diffusion. The diffusivities of corticosterone in the EVA
polymer (5.9× 10−13m2/sec) and skin (4.4× 10−12m2/sec) were measured at 37 ◦C. To
obtain the activation energy, the diffusivities at different temperature are required. Instead,
it is assumed that the diffusivity is doubled in the skin and tripled in the EVA polymer for
the temperature elevation by 10 ◦C(i.e., a rule of thumb used in chemical reaction kinetics).
From Equation (3.46), this assumption leads to Ea of 57.17 kJ/mol for the skin and 90.607
kJ/mol for the patch, respectively. These values show similar orders of magnitude to those
reported for desoxycorticosterone and testosterone in a silicone membrane [43].
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3.3.3 Design Parameters
In line with the previous definition, a design parameter is a factor that has a strong influ-
ence (compared with other parameters) on the transdermal delivery of corticosterone to
the systemic circulation. It can also be easily manipulated in the device design. In the
heat-enhanced transdermal delivery protocol, five design parameters are suggested: initial
reaction rate; mass of pad; overall heat transfer coefficient; and initial concentration.
Initial reaction rate (IR=k1C
2
Iron,0) refers to the chemical reaction rate when iron
powder is just exposed to the oxygen gas. This determines the speed of the oxidation of
iron and estimates how long the exothermic reaction persists during the treatment. The
control of the initial reaction rate is very important. A sonophoresis or an iontophoresis
contains an electronic device to control the magnitude of the enhancement. However, the
chemical reaction, once it is initiated, takes place spontaneously and cannot be stopped by
an external factor. Fast initial reaction rate will result in a fast release of heat in a short
time, and thus high temperature will be quickly achieved. Without a proper control of the
reaction rate, an extremely high temperature can cause thermal injury. In addition, the
exothermic reaction will not persist longer, and thus the thermal effect will vanish earlier
than necessary due to the quicker cooling down of the pad. The amount of heat released is
related to the amount of iron powder. The concentration notation in the initial reaction rate
is valid for a homogeneous reaction. In the heterogeneous reaction, reaction rate depends
more on the surface area. In other word, the initial reaction rate can be controlled by
manipulating the particle size distribution of iron powder.
Mass of pad (MS=m) refers to the amount of the contents included in the heating
pad except iron powder: the filler materials. As mentioned before, the filler material plays
a role in deciding the heat capacity of the pad and also controls the release of heat to
the patch. A commonly-used hand warmer contains 12.5 g of iron powder and the filler
materials in a pouch. A patent shows that the weight ratio is 5 (activated carbon) : 16
(iron powder) : 3 (saw dust) : 2 (sodium chloride) : 6 (water) [55]. Hence, the efficacy of
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transdermal delivery protocol can be examined in two ways: 1) considering the contents
as pseudo-binary mixture (iron powder and the filler materials), the protocol is tested for
various amounts of the filler materials with the amount of iron powder fixed, 2) the protocol
is tested without changing the mass of pad. In the former case, the mass ratio in the filler
materials is conserved. The manipulation of the mass of the pad is achieved by simply
adding the filler materials to the pouch.
Overall heat transfer coefficient (OH=U ) is the reciprocal of the resistance to the
transport of energy through the layer located between the heating pad and the drug-loaded
polymer. Since the backing material acts as a valve of the flow of heat from the pad to
the patch and the skin, the overall heat transfer coefficient has significant influence on the
temperature profiles in the patch and the skin and, as such, influence the enhancement of
drug delivery. The manipulation of the overall heat transfer coefficient can be achieved by
the choice of the backing material. A thick backing material provides high resistance to
heat transport (small overall heat transfer coefficient). In addition to the thickness, the type
of backing material also affects heat transport.
Initial concentration (IC=C0) of corticosterone in the patch is related to the rate of
drug release to the body since the diffusion is a transport mechanism driven by the concen-
tration gradient. If the EVA polymer is blended with a large amount of corticosterone, the
initial concentration will be high, and thus fast drug absorption can be achieved. However,
the initial concentration is directly related to the dosing size (i.e., financial factors). Even
though this research does not take the economics of the drug delivery protocol into account,
the price of the active pharmaceutical ingredient (corticosterone in this study) is one of the
most important factors in the development of new products. Therefore, the protocol in this
research needs to be developed considering the minimal use of valuable drugs to avoid
wastes.
Finally, thickness of patch (LII) is also considerable. It accounts for ratio of amount
of API remaining after treatment to the initial dose. Especially, the diffusivity of corti-
54
costerone is much smaller than other transdermally-transported materials such as fentanyl
citrate. Slow diffusion causes a boundary-layer-like concentration profile through a thick
patch, which means drug release has taken place only at the front (to the side contacting
with the skin). And thus great amount of corticosterone blended in the polymer will be
unused. On the other hand, too much thin patch may be able to minimize waste of drug
after a treatment. However, the desired supply (flux to systemic circulation) of APIs may
not persist long. It is worth noticing that thickness of patch was not a design parameter in
the previous study.
3.4 Results and Discussions
In this research, the analysis on a heat-aided transdermal corticosterone delivery has been
performed for one-time application of patch. Period of therapy is set to 7 days (a week).
A week-long therapy is common for such hormone as corticosterone since required flux
is very small (Jset = 1.2× 10
−5 mg/cm2hr [57]). The repeated applications of transder-
mal patches keep a patient in a continuous therapeutic range (quasi steady period). This
problem was addressed in a prior research [3].
Prior to proceeding with the mathematical model derived early in this study, the val-
idation of the theoretical model is required to support feasibility of rest of the research. For
this purpose, data of serum concentration as time obtained from set of clinical experiments
are employed. Since the experimental conditions are quite different from that described so
far, the modification of the original mathematical model has been made.
3.4.1 Validation of Mathematical Model
The mathematical model developed so far is used to provide information on design of trans-
dermal corticosterone (or any other drug) delivery patch with an external heating source. In
spite of useful advantages of the protocol, the validation of the modeling approach should
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be done before releasing it for ongoing pharmaceutical researches. In the validation, clini-
cal experimental results are critically required.
Clinical data, retrieved from [9], are used in the validation of the proposed mathe-
matical model. In the experiments in [9], a transdermal patch (Duragesic®) that delivered
25 µg/h of fentanyl to 10 healthy subjects was applied. The serum concentrations were
monitored for 36 hours during which blood samples were taken, analyzed and recorded
every hour. The tests were performed in four sessions (called A, B, C and D, respectively).
In sessions A and B, a patch is worn to each subject for first 30 hours, and is removed then.
In session A, a heating pad is applied over patch for 1 hour starting at 24 hour. In session
B, a heating pad is applied for the first 4 hours and removed. Then another heating pad is
applied again during the 24 to 25 hour period. Temperature of a heating pad is assumed to
be 42 ◦C. Sessions C and D are not suitable for this validation. Serum concentrations as
time in each session that will be used in the rest of this study are taken from Figure 1 of
[9].
The modification of the original mathematical model is also required to suit the
experimental data. Although the heating pads worn by the subjects were identical to that
described in this work, no detailed description of the pad is given except a temperature
rise of 42 ◦C. In addition, Duragesic® is a reservoir-type patch whereas a matrix-type
patch is used in the original model. A reservoir-type patch can maintain a constant drug
concentration in the polymer material for a long time. In this case, the existence of the
polymer material is not significant, and thus the mass and heat transports through the patch















































T̄III |x=0 = 42







= hκII (T̄II −Ta) others
, (3.52)








T̄III |t=0 = 37
oC. (3.55)
The temperature of air, Ta, is kept at 25
◦C, and the heat transfer coefficient is
20 W/m2K [58]. The heat conductivity of the patch, κII , is not known, and hence the
same value as used in the original model is assumed. The dimensionless expression is not
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used in this modified model. The partition coefficient of fentanyl is 860, and the constant
concentration of the patch is 164 µg/mL [59]. Even though the model that is intended to
be validated has been slightly simplified, the important feature of the original model (i.e.,
the thermal enhancement of diffusion) is still represented well by the new equations. The
















where Cserum is a serum concentration of fentanyl, VB and kE are the volume of distribu-
tion and the elimination rate constant of fentanyl, respectively. Specific steps to validate
the original model using the modified system, Equations (3.48) to (3.56), is summarized as
following: 1) the serum concentrations up to first 12 hours in sessions A and B are involved
in the study, 2) as many physical and other properties as possible are collected from liter-
atures, 3) the modified model with applied local heat is fitted to the serum concentrations
in session B (some uncollected parameters may be determined here), 4) using the physical
property values in step 3), the modified model without heat is predicted for the first 12
hours, 5) the modified model is successfully validated if the predictions in step 4) agree
with the experimental data. The implementation of only the first 12-hours data is relevant
because unchanged physiological conditions of human subject are expected for such short
period. Unlike the mathematical model, biological conditions of human are continuously
changing due to various factors. One and half day (i.e., 36 hours) is too long period for
those conditions to remain unchanged. They eat, move, and even sleep during that time.
And continued exposure to a drug also changes pharmacokinetic parameters of that drug.
In these reasons, unexplainable behaviors (e.g., jump of serum concentrations) are often
observed in Figure 1 of [9].
The result of the steps 1) to 5) are shown in Figure 3.3. The volume of distribution,
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VB, and the elimination rate constant, kE , of fentanyl are set 3 L and 0.6 hr
−1, respectively.
When fitting the modified model to the data of session A, two pharmacokinetic parameters
are estimated: effective diffusivity of fentanyl, DIII=1.45×10
−9 m2/s, and the activation
energy of the effective diffusivity of fentanyl through skin, Ea=114.34 kJ/mol. With these
values and the same model, the experimental data of session A are predicted and the results
are shown in Figure 3.3. In Figure 3.3, a good agreement is observed between the model
prediction and the experimental data. Therefore, the modified and original models of the
transdermal drug delivery system with heat enhancement are verified. This finding justifies
the development of a design protocol based on the mathematical representation. The model











































Figure 3.3 Expected temperature and concentration profiles observed throughout the treat-
ment by the transdermal drug delivery protocol used in this research.
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3.4.2 Optimal Design of Heat-Enhanced Transdermal Drug Delivery
The design parameters defined are the initial reaction rate (IR), mass of heating pad (MS),
overall heat transfer coefficient (OH), initial concentration of patch (IC), and thickness of
patch (TH). For the patch thickness, specific values of 0.5 mm, 1 mm, 2 mm and 3 mm are
selected in the optimization. Compared to other factors, variation in TH contributes less to
the flux. Rather, the patch thickness is related to the effective use of drug. Consequently,
no high-precision tuning is required for TH. The values of IR and MS are fixed at 12.375
g/cm3hr and 12.5 g. In previous work, the two factors, IR and MS, were ranked 2nd and 3rd,
respectively, among four parameters as having the most significant impact on the desired
flux [3]. Nevertheless, from experiences and theoretical considerations, these parameters
were excluded from the list of design parameters and set at specific values for the following
reasons. Because the diffusion of corticosterone through either patch or skin is very slow,
the treatment period is long. Under this condition, simulation results showed long dormant
and exponential periods. In order to shorten these periods, the initial oxidation rate is
likely to increase so that a high temperature can be achieved. Also, the mass of the heating
pad also tends to increase to ensure a prolonged effect of an external heat source. Those
trends that cannot be controlled systematically by the developed computer program yield
two disadvantages: skin burn due to the high temperature and an inconveniently heavy
device. To circumvent these drawbacks, the analysis should be more case specific so that
the problem is solved for a limited number of design parameters. Therefore, the mass of pad
(MS) is fixed to 12.5 g, which is the weight of common hand-warmer [55]. Also, to avoid
thermal injury, the initial oxidation rate (IR) is determined so that the 99 % conversion of
iron powder is achieved 10 hours after the treatment begins; this leads to an IR of 12.375
g/cm3hr. The program is designed to display whether the input parameters cause skin burn
or not. The sets of values of design parameters that result in thermal injury are excluded in
the optimization.
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With the patch of 0.5 mm thick, the optimum design is obtained: OH=1.881 J/cm2hrK
and IC=65.02 µg/cm3 with the resulting ISE=0.1097. Note that the units of mass, length
and time are gram, centimeter and hour, respectively while and others follow SI units. The
unconventional unit selection has benefits in the numerical solutions of the governing equa-
tions and decreases the optimization time. At the end of the simulations and optimizations,
those values are reported in the SI units. Concentration profiles in the patch and skin over
the treatment period are showed in Figure 3.3. The discontinuity at the boundary between
patch and skin is observed due to the equilibrium condition applied at the interface. After
the treatment ends, around 2 % of the initial corticosterone remains. The temperature dis-
tributions and the flux at this optimal design are shown in Figures 3.5 and 3.6, respectively.
Since this transdermal drug delivery system is cooled down nearly to the initial temperature
within the first 12 hours of the treatment, it is said that the heat is used merely to promote
the initial diffusion and absorption of drug to the capillary. The maximum allowed temper-
ature is 55 ◦C, and no skin burn will occur. It takes about 2 days for the flux to reach the
desired level, and it persists for 3 days. Hence, parallel administration with other dosage
form should be suggested to maintain the serum concentration of corticosterone during this
time. Note that the flux does not meet the need for the remaining 2 days.
With a 1 mm-thick patch, the optimum design is obtained OH=1.646 J/cm2hrK; and
IC=51.74 µg/cm3. The concentrations of corticosterone are shown in Figure 3.7. Those
settings lead to 68.9 % of the drug consumed during 7 days. The remaining corticosterone
may be helpful in case a patient forgets to replace the patch with a new one. According
to Figure 3.8, no skin burn occurs, and the system is cooled down in the first 12 hours.
Figure 3.9 shows that it needs 3 days to reach the desired flux. This is longer than 2 days
with a 0.5 mm patch. However, the overshoot of flux is moderate and the flux changes
within a narrow range in the quasi-steady region. Moreover, after the end of treatment, the
































Figure 3.4 The concentrations of corticosterone in the patch and the skin during the treat-

























Figure 3.5 The temperature distributions in the 0.5 mm-thick patch and the skin.
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Desired Flux




















































Figure 3.7 The concentrations of corticosterone in the patch and the skin during the treat-


























Figure 3.8 The temperature distributions in the 1.0 mm-thick patch and the skin.
Desired Flux






















Figure 3.9 Flux during the treatment period with the optimally designed 1.0 mm-thick
patch.
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The concentration distributions, temperature distributions and the fluxes of corti-
costerone are illustrated in Figures 3.10 to 3.12 for a 1.5 mm. Similar profiles are shown in
Figures 3.13 to 3.15 for TH=2.0 mm; Figures 3.16 to 3.18 for TH=2.5 mm; Figures 3.19
to 3.21 for TH=3.0 mm-thick patches at their optimum design. For those setups, no skin
burn is observed, moderate overshoots in the fluxes are obtained and the final fluxes are all
above the desired level. The temperatures of the systems get back to the body temperature
after around 12 hours. This shows that the determination of the initial reaction rate (IR)
is reasonable since the reaction is completed before the system cools down. Two to three
days are inevitably required to achieve the desired flux level. Therefore, it is concluded































Figure 3.10 The concentrations of corticosterone in patch and skin during the treatment


























Figure 3.11 The temperature distributions in the 1.5 mm-thick patch and the skin.
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Figure 3.13 The concentrations of corticosterone in patch and skin during the treatment

























Figure 3.14 The temperature distributions in the 2.0 mm-thick patch and the skin.
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Desired Flux






















Figure 3.15 Flux during the treatment period with the optimally designed 2.0 mm-thick
patch.
The optimal designs for all case studies are summarized in Table 3.1. The ISE
represents a measure of the drug therapy to reach the desired delivery rate. The smaller the
ISE, the closer the actual flux target is to the target or prescribed flux. Table 3.1 shows that
the ISE value increases with the patch thickness at the exception of the 3.0 mm-thick patch.
The implication is that a thinner patch if preferred to effectively deliver corticosterone into
body.
Table 3.1 Optimum Design Parameters of Transdermal Corticosterone Delivery System
Enhanced by External Heat Source
Thickness IR MS OH IC
ISE
[mm] [g/cm3hr] [g] [J/cm2hrK] [µg/cm3]
0.5 12.375 12.50 1.8809 65.02 0.109653
1.0 12.375 12.50 1.6458 51.74 0.116883
1.5 12.375 12.50 1.7872 52.33 0.117121
2.0 12.375 12.50 1.8190 51.96 0.117232
2.5 12.375 12.50 1.7758 53.12 0.117333































Figure 3.16 The concentrations of corticosterone in patch and skin during the treatment

























Figure 3.17 The temperature distributions in the 2.5 mm-thick patch and the skin.
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Desired Flux






















Figure 3.18 Flux during the treatment period with the optimally designed 2.5 mm-thick
patch.
Table 3.1 lists other useful quantities resulting from the design. In Table 3.1, the
“drug consumption” denotes the amount of drug to be blended with the polymer in a unit
area of patch, and is calculated by multiplying the initial drug concentration by the thick-
ness of the patch. Note that the use of thicker patch increases the expenses of corticos-
terone. The “ratio released” is the percentage of corticosterone that has been released dur-
ing the treatment out of the total amount embedded initially. The amount of corticosterone
that is released from the patch (including the fraction that is absorbed into the body and the
residual amount that remains in the skin) does not change significantly from one design to
another. On the other hand, the “residue” (defined as the amount of corticosterone remain-
ing in patch per square centimeter after treatment) monotonically decreases with increasing
TH. As a result, even though a very thin patch is the best option, from a financial perspec-
tive, the 0.5 mm-patch does not satisfy the therapeutic need for the last 2 days, which may































Figure 3.19 The concentrations of corticosterone in patch and skin during the treatment

























Figure 3.20 The temperature distributions in the 3.0 mm-thick patch and the skin.
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Desired Flux






















Figure 3.21 Flux during the treatment period with the optimally designed 3.0 mm-thick
patch.
1.0 mm or thicker can provide sufficient drug for a 7-day treatment. Therefore, taking the
efficiency and the safety issues into account, a 1.0 mm-thick, corticosterone-loaded patch
with its optimal design parameters is the best choice for a week-long therapeutic treatment.
Table 3.2 Summary of Transdermal Corticosterone Delivery System Enhanced by External








[mm] [µg/cm2] [%] [µg/cm2] [µg/cm2]
0.5 3.25 97.95 3.18 0.07 No
1.0 5.17 68.9 3.57 1.61 Yes
1.5 7.85 46.99 3.69 4.16 Yes
2.0 10.39 35.29 3.67 6.72 Yes
2.5 13.28 28.23 3.75 9.53 Yes
3.0 15.79 23.52 3.71 12.07 Yes
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3.4.3 Relative Impacts of Design Parameters on Drug Delivery
An optimum design for a heat-assisted transdermal patch was developed using mathemat-
ical modeling. A 1.0 mm-thick patch, that enhances the effectiveness of the treatment and
addresses safety issues, was recommended. The next task is to assess the relative impacts
of design parameters on the desired drug delivery rate. This analysis is important to man-
ufacturers because it will show to what extent deviations of some critical parameters from
their nominal values influence the performance of the device.
Similar analyses were performed for the heat-enhanced transdermal drug delivery in
[3]. Nevertheless, the mathematical model was slightly modified: infinite domain defined
for heat transfer. Hence, it is important to check whether the change made here affects the
relative impacts of the design parameters.
Two parameters (i.e., p1 and p2) are first selected. A three-dimensional Cartesian
coordinate system is used so that two axes are occupied by p1 and p2, respectively. The
domains of p1 and p2 are defined from 80 % to 120 % of the optimum values for p1 and
ps. The other model parameters are set at their nominal (i.e., optimum) values. The error
(ISE) is plotted on the third axis. This error is evaluated at points (p1, p2) to produce a
surface. Since the center of the p1-p2 plane denotes the optimal setting (i.e., the lowest
ISE), the expected shape of the ISE surface is a cup which is open to the top. The vertex
is placed at the center. However, experiences show different results (e.g., planar). This is
because the optimization procedure searches for parameter values that do not violate certain
constraints. To facilitate the mathematical optimization, proper domains of variables should
be predetermined. On the other hand, this study does not provide such domains until the
equations are solved using the given parameters. The program script is written in such a
way that a given set of parameters is omitted if the results cause thermal injury. Therefore,
assessment of the impacts of two parameters is not straightforward. Some suggestions are
given below:
• with a planar surface, the higher-impact parameter shows larger magnitude of gradi-
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ent along the associated axis,
• with a bent surface, the higher-impact parameter forms a U-shaped cross-section
when the surface is cut by a plane perpendicular to the axis associated with the other
parameter,
• with a cup-shaped surface, the higher-impact parameter yields greater second partial
derivatives along the associated axis at the center.
In the prior study, six combinations were compared to rank the four design parame-
ters [3]. The results were (from the most to the least influential parameter): initial concen-
tration (IC), initial reaction rate (IR), mass of heating pad (MS) and overall heat transfer
coefficient (OH). Although IR and MS were not supplied to the optimization routine, their
relative contributions are important to the process. Therefore, six tests are performed in
this study, as well.
The optimum design with the 1.0 mm-thick patch is used in the analysis. The results
of six tests are: SMS > SIR (Figure 3.22, SIR > SOH (Figure 3.23, SIC > SIR (Figure 3.24,
SMS > SOH (Figure 3.25, SIC > SMS (Figure 3.26 and SIC > SOH (Figure 3.27 where Sp is the
sensitivity of a parameter p. Consequently, the ranking of the relative impacts is: SIC > SMS
> SIR > SOH . The overall trend is similar to that of the previous work; the only difference
is that MS precedes IR with this model. However, this does not invalidate the conclusions
from the two models. Compared to the model outlined in [3], the temperature-dependent
absorption of corticosterone at the boundary between the skin and the body core contributes
much more to the overall drug delivery. Thus, the duration of a high temperature of skin,
as well as the patch and heating pad, is of importance. Note that, in the old model, the
boundary is isothermal, and hence, the absorption is not affected by the persistence of
heating. It should be noted that the factor controlling the duration of heating is the mass of
heating pad, i.e., MS (or amount of fuel). Therefore, the sensitivity test with the new model

















































































































Figure 3.27 ISE surface on the IC-OH domain.
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3.5 Conclusions
A mathematical model was derived to investigate the dynamics and the design problems in
the transdermal drug delivery system enhanced by the external heat source. The mathemat-
ical expressions describe key pharmacokinetic phenomena that take place in a transdermal
route:
1. change in temperature of an external heating pad due to an oxidation of iron and heat
loss to a patch,
2. the diffusion of an API and the conduction of heat through two adjacent membranes,
i.e., patch and skin,
3. a pseudo equilibrium of an API at the interface between the two membranes,
4. flux of an API due to absorption through capillaries.
Validation of the mathematical model based on clinical experimental data shows
that the modified model agrees well with the real pharmacokinetics of the transdermal
fentanyl delivery with and without heat. This result is used as a good evidence that the
mathematical model and subsequent design protocol can be implemented for answering
questions in the related pharmaceutical sectors.
The numerical solutions of the partial differential equations are the transient dis-
tributions of concentrations and temperatures through the patch and the skin. Mass and
energy were conserved which showed the integrity of the model, solution procedure and
computer program. The implementation of these solutions in the design of the suggested
protocol is performed by 1) identifying a set of design factors and discussing how they can
be manipulated [3], 2) finding optimal values of those parameters based on how close the
flux is to a desired level, and 3) listing them in the order of the relative sensitivity to the
optimal delivery. There are five design parameters [3] that show priorities in controlled re-
lease of corticosterone: mass of a heating pad (MS), initial oxidation rate (IR), overall heat
78
transfer coefficient (OH), thickness of patch (TH), and initial corticosterone concentration
in a patch (IC).
Due to the modifications made in the model of this research from that of the previ-
ous work [3], i.e., heat is transported deeper into the body than corticosterone. Infinitely
large values of the first two design parameters, MS and IR, are required, in theory, for the
mathematically optimal release, which would cause a thermal injury in the practical ther-
apy. To prevent the undesired skin burn, three actions are taken in the computer program
written in Mathematica® environment: MS is fixed at 12.5 g based on the patent [55], IR is
determined 12.375 g/cm3hr based on the setting that 0.99 conversion of iron is achieved for
10 hours, and the optimization process is designed so that it monitors the maximum skin
temperature every single iteration and gives a warning sign when the temperature is over
the safety margin (55 ◦C). As a result, the optimal release of corticosterone is achieved by
making the suggested transdermal delivery protocol so that OH=1.6458 J/cm2hrK, TH=1.0
mm, and IC=51.74 µg/cm3. The decision is made to take into account not only the abil-
ity to reach a desired flux (see Table 3.1) but also the safety and the effectiveness of the
treatment (see Table 3.2).
CHAPTER 4
ELECTRICALLY-ENHANCED SOLUBLE MICRONEEDLE PATCH
Microneedle Therapy System (MTS) is one category of transdermal drug delivery sys-
tem where medicine is transported through the skin by diffusion [59-64]. As discussed in
Chapter3, stratum corneum is the thinnest layer but definitely the most significant barrier
in transdermal delivery. In spite of difficulties associated with the transport of substances
through the stratum corneum, the transdermal route remains a very favorable alternative to
other forms of administration. Hence, in addition to applied heat treated in Chapter 3,there
have been continued efforts to control and accelerate drug passage through this layer by
introducing various drug delivery enhancers. For instance, some non-toxic chemicals (e.g.,
simply water) have an ability to loosen textures, widen and hydrate pores of skin when it is
mixed with or applied prior to APIs (chemical enhancers). With such tunnel-making mech-
anisms, molecules of APIs can be easily diffused into deeper skin. As a physical enhancer,
low-frequency ultrasound is widely used because the sound waves are capable of increas-
ing the skin permeability [69, 70]. Weak electric current can be applied to facilitate the
active transport of molecules through the stratum corneum [68, 66, 67]. Drug delivery im-
provement mechanism of MTS is to pierce stratum corneum with an array of microneedles
to make micropores through which medicine passes without resistance of stratum corneum
[61, 60]. Despite poking small holes in the skin, microneedles cause no pain or serious
injury because nerves are not irritated by microneedle of length ranging from 200 µm to 2
mm according to specific purpose [61].
There are two representative types of microneedles:
Solid microneedle The major function of this kind is to pierce stratum corneum to make
microchannel. After insertion, the patch is removed for following treatment with
medicine. For this reason, it is fabricated by etching metal or molding polymer [61,
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77]. Cone, pyramid or other shape of microneedle is possible [78]. Recently, coated
microneedle with APIs is also available so that drug can be introduced quickly into
skin [79, 80, 81].
Hollow microneedle This microneedle contains microchannel which serves for the release
of APIs or the suction of body fluid through micropump (Poiseuille flow) after in-
sertion [82, 83, 84, 85]. When it is connected to lab-on-a-chip analyzer, this kind of
microneedle can be implemented as probe of biosensor monitoring and diagnosing
body glucose level of patients who have diabetes [86, 71].
Self-dissolving microneedles are advanced forms of solid microneedles. The nee-
dles are made of water-soluble substances such as glucose or biodegradable polymers
mixed with APIs. After insertion, the microneedle starts to degrade releasing medicine
beneath skin. This patch is removed when all needles disappear.
At this point, new transdermal drug delivery system needs to be suggested for
achieving low cost and promoting greater patient compliance. In addition, development
of mathematical model that can be used in analysis and control of the drug delivery system
is required. Simulations based on developed mathematical model provide future experi-
mental and manufacturing guidelines.
4.1 Problem Statements
In this research, the author proposes a parallel use of electric current (iontophoresis) and
self-dissolving microneedles. Figure 4.1 illustrates the structure of the proposed patch. The
cathode is also an insoluble microneedle made of metal or conductive polymer. The anode
is placed at the center of drug-loaded soluble microneedle. Two lines from cathodes to
anodes are connected via power supply (not shown). To avoid any confusion caused by
long names, hereafter, let electrode refer to cathode, microneedle to drug-loaded soluble
microneedle containing anode at its center, body to the depth where capillary vessels and
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nerves are found (in some cases, it also denotes systemic circulation), and epidermis to
space between stratum corneum and body.
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Figure 4.1 Array of microneedles and electrodes in alternate order on patch substrate
(figure not drawn to scale).
Despite the curvature in a real skin surface, Cartesian coordinates can be employed
because of the very short height of microneedle compared to the width of the patch. In
Figure 4.1, two horizontal axes, x and y, denote a direction parallel to surface of skin,
while vertical axis is perpendicular to the skin surface. On a single patch substrate (at the
bottom enclosed by thick line), electrodes and microneedles are placed in an alternating
order and inserted simultaneously. Drug absorption takes place at the boundary between
epidermis and body (i.e., top face of Figure 4.1 which is encompassed by thick dashed
line). The space between the patch substrate and the layer encircled by thin line denotes
the stratum corneum. Although the skin is composed of various layers that have different
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physiological functions, a single layer assumption has been adopted. It will provide a
good and convenient approximation of drug delivery from an engineering standpoint. The
primary direction of drug delivery is determined based on a sense that drug transport in the
direction is directly related to drug absorption. Note that cathode is expressed as a negative
terminal, which implies this study focuses on the drug delivery through skin.
Synergistic effects of coupled physical enhancers (soluble microneedles and ion-
tophoresis) had already analyzed in prior work [12]. In in-vivo tests, soluble-microneedle
patch was first placed on a hairless rat skin for 90 seconds during which all micronee-
dles disappear. After the patch was removed from the skin, a constant electric current was
applied for 60 minutes using iontophoresis device. The results were positive: a 25-fold
enhancement was achieved using both microneedle and iontophoresis in the delivery of
methotrexate compared to individual application of iontophoresis or microneedle [12].
Although a sequential application of two individual drug-delivery systems has al-
ready been attempted, the newly proposed platform has the following differences when
compared to the old technology:
1. the electrodes and the microneedles are inserted into skin,
2. the electric current is applied while the microneedles are being dissolved,
3. thus, distance between the cathode and the anode is very close.
Drug carrier in both platforms is a space charge (i.e., electrically charged particle).
Ions are the best candidates for the carriers. However, nonpolar particles can also serve
as drug carriers since induced dipole makes them polar temporarily under an electric field
depending on the polarity of the species. As a result, drug-delivery enhancement scenario
of the proposed platform is as follows:
1. first, applied electric field accelerates diffusion of drug molecule from microneedles
toward electrodes (i.e., secondary direction of drug delivery in Figure 4.1),
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2. increased diffusion leads to
a. fast outspread of drug over skin,
b. lower drug concentration around microneedle,
3. drug absorption is enhanced due to
a. wider area of diffusion to primary direction of drug delivery in Figure 4.1,
b. increased dissolution of microneedle.
A quicker dissolution by applied electric field is achieved since the driving force for dis-
solution is the deviation of drug concentration around the solid from its solubility. Using
sequential applications of microneedle patch and iontophoresis [12], this effect cannot be
attained. For this reason, the term “electrically-enhanced” or equivalents will be used to
describe current platform instead of iontophoresis, although both share the same physical
mechanism.
Another design of parallel applications of microneedle and electric current is also
possible as shown in Figure 4.2. Unlike the original platform, cathode and anode are not
inserted into skin. Indeed, after soluble-microneedle patch has been worn on the skin, the
patch substrate is covered with a sheet of anode while a sheet of cathode is attached to
a different location on the skin, as in iontophoretic delivery. In Figure 4.2, dashed line
from microneedles to the cathode represents an electric field, with an electromotive force
tangential to it. Drug absorption occurs due to diffusion to the body (primary direction of
drug delivery). For both platforms, the role of the electric field is to activate drug motion













Figure 4.2 Different design of parallel application of microneedle and electric current in
transdermal drug delivery.
Advantages of this design are that the fabrication of the microneedle array is much
simpler, and that currently-developed products can be utilized in treatment. However, in
patients’ (in other word, customers’) point of view, the original platform can be much more
beneficial because of:
• low energy consumption,
• no console may be required,
• light-weighted unit.
The key difference between the two platforms is the distance between cathode and
anode, ∼500 µm (i.e., 0.5 mm) in the original design and ∼1 cm (i.e., 10 mm) in the other
option. This difference results in a lower energy consumption. According to Ohm’s law, the
current is directly proportional to the voltage and inversely proportional to the resistance.
The latter is directly proportional to the distance between the electrodes. Based on this
85
observation, only one twentieth voltage is required for the original system to produce the
same current as design shown in Figure 4.2. Even though the actual energy saving may be
less than the estimated value, it should be significant.
Iontophoresis modules, e.g., LidoSiteTM (Vyteris Inc.), usually require consoles for
controlling electric current. These consoles contain expensive preprogrammed micropro-
cessors [87, 88], which increases not only controllability of drug delivery but also manu-
facturing cost.
The above features can also result in reduced battery size and, consequently, a
smaller product. The proposed drug delivery platform consists of only a single patch and a
power supply. To fully appreciate the benefits of the device, it is necessary to derive ana-
lytical models and develop computational tools to facilitate simulations.
4.2 Preliminary Studies
Even though the advantages of microneedle combined with electric current are qualitatively
shown above, no clinical data has been found to support the feasibility of the proposed
platform and to be used for model validation. The absence of relevant experimental results
to be compared with outcomes of this research may raise issues that can make further
investigations useless. Therefore, sets of preliminary studies are conducted to indirectly
prove drug delivery enhancement of the new platform.
4.2.1 Pilot Experiment I: Electrically Activated Diffusion of Ink
Active diffusion of dissolved Indigo Carmine powder (Matheson Coleman & Bell, Gar-
dena, CA) by a DC power supply (Hewlett Packard, Harrison 6202B) is qualitatively com-
pared to passive diffusion. Indigo Carmine is a pH indicator that shows blue color in a
neutral solution. To conduct the experiment, two 1 7/8” ID Petri dishes are filled with
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pieces of cheesecloths (VWR Scientific, Bridgeport, NJ) and water (mimicking immobile
viable cells and body fluid), respectively. Electrodes are 3/8” wide and 1” long aluminum
foil. They are immersed in one Petri dish. The voltage is kept at 38V. Instrumental setup is
illustrated in the left picture of Figure 4.3. The left electrode is cathode (+).
Evolutions of inks are shown in pictures on the right in Figure 4.3. Indigo Carmine
powder is initially placed at the center of each Petri dish. Electrodes are placed only on one
dish. A stopwatch is used to record movements of inks as time. After five minutes, ink on
the right dish has diffused out more than that on the other dish has toward cathode. From
the observations, it is proven that applied electric field improves molecular diffusion. In
addition, it is important to note that direction of motion is toward cathode which is same as
that of electron.
Figure 4.3 Experimental setup (left) and observations (right) of the first preliminary study.
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4.2.2 Pilot Experiment II: Dissolution Enhanced by an Electric Field
Another feature of the proposed platform is that applied electric current improves dissolu-
tion rate of microneedle. To validate this scenario, an experiment has been performed with
cough drops containing 6 mg of benzocaine. Similar instrumental setup to the previous
experiment has been used. Instead of Indigo Carmine powder, cough drop is placed at the
center of each dish. Weights of two lozenge have been carefully measured at specific times
during experiment for calculations of fractional releases of benzocaine. It is assumed that
6 mg of benzocaine is uniformly distributed in a lozenge.
Experiments are conducted twice: during the first experiment, weights of lozenges
are measured with caution for 27 minutes. In the second test, only initial and final weights
are measured. The reason is that measuring actions inevitably cause disturbances to tranquil
lozenges and may result in unexpected drug loss, the impact of which to dissolution of
lozenge may be unpredictable or sometimes suppress effect of electric field. Thus, the first
experiment should be repeated until weights of lozenges at 27 minutes are acceptably close
to those in the second experiment (e.g., ±5%) in order to guarantee that the first experiment
is performed under a disturbance-free condition as much as possible. Another reason of the
second experiment is to investigate processes of changing shapes of lozenges, which can
provide helpful insight into enhancement scenario of dissolution by electric current.
The results of the first experiment are shown in Figure 4.4, in which fractional-
release profiles of benzocaine from each lozenge are shown and extents of enhancements in
percentage are also plotted. The lozenge under an influence of applied electric field released
more benzocaine than the counterpart did. An averaged enhancement for 27 minutes is 5.84
%, it is calculated by dividing area under curve by 27 minutes.
As a result of the second experiment, approximately 72 % of benzocaine is released
in the presence of electric field which is induced by DC 40V, while 70 % is released without
electric current. Only 2% improvement in this in vitro lozenge dissolution test seems not















































































Figure 4.4 Fractions of benzocaine released from two lozenges and percentage of enhance-
ment by applied electric field.
that effect of electric field is magnified in smaller scale, significant enhancement can still
be expected with a real microneedle patch.
Also, comparison of the shapes of remaining lozenges provides much more im-
portant information for advocating the proposed drug delivery enhancement scenario. In
Figure 4.5 (a), the lozenge is placed between electrodes (cathode is at left), while no elec-
tric current is applied in Figure 4.5 (b). Lower right corner of lozenge in Figure 4.5 (a)
definitely seems to be much more degraded than the other corner of the same lozenge. The
cheesecloth around cathode is much darker (i.e., more concentrated with dissolved lozenge)
than that around anode. This can be explained by the theory such that dissolved lozenge
moves toward cathode (to the left), this causes lower concentration around that corner than
used to be, and thus, dissolution occurs at higher rate. On the other hand in Figure 4.5 (b),
dissolution of lozenge takes place evenly on entire wet surface because diffusion, in this




Figure 4.5 Shapes of remaining lozenges after 27 minutes in the second experiment.
4.2.3 Theoretical Consideration of a Dissolving Microneedle
In addition to the previous laboratory experiments, a mathematical model of a dissolving
conical needle has been considered. In this model, a conical needle is submerged into a
container filled with liquid of volume vE . Liquid represents epithelial fluid and is agitated
well so that drug concentration, c, in liquid is assumed to be uniform. Dissolution of
drug-containing cone (rate constant=kD) results in supply of drug into liquid. First-order
elimination of drug takes place in liquid (rate constant=kL). Side-view description of this
model is given in Figure 4.6. Degradation of cone is assumed not to change the apex angle,
2θ . Thus, the size of remaining microneedle can be expressed only by its height, h. The


























Figure 4.6 Physical configuration of a dissolving conical microneedle in epidermis.
dc
dt
= − (kLc) +
(ρ − c)










where ρ and cs are density and solubility of cone, respectively. Volume of cone is denoted
by vC Initial value of every variable is marked with subscript 0. Before dissolution, no drug
exist in epidermis, i.e., c0 = 0.













Dimensionless height of cone and concentration are H = h
h0
and C = c
cs
, respectively. Char-
acteristic time is defined as τ0 =
ρh0 sinθ
kDcs















dimensionless density. The capacity α is the ratio of maximum amount of drug that can be
accommodated in initial volume of epidermis to dosage size. Initial conditions are given at
τ=0 as
H = 1, (4.5)
and
C = 0, (4.6)
respectively.
Two limited cases are analyzed: infinitesimal k1 and large α. In the former case
where k1 → 0 (i.e., negligible elimination, concentration and cone height after long time, C∞
and H∞, respectively, depend on α. If α < (ρ̄ −1), epidermis becomes saturated with drug







. And if α > (ρ̄ −1), dosage size contained in the cone is not sufficient
to saturate liquid in epidermis, and C∞ =
ρ̄
(α+1)
and H∞ = 0 (i.e., complete dissolution). In
the second case, where α → ∞, the volume of epidermis is very large enough to neglect
change in drug concentration, i.e., C=0. This is attained when tip-to-tip distance in an
array of microneedles is sufficiently long. Applying these restrictions to Equations (4.3)
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and (4.4) leads to
H = 1− τ. (4.7)
By letting H=0 in Equation (4.7), the time lapsed before microneedle disappears, τD, is
obtained




This value can be used to estimate dissolution rate constant of a microneedle from experi-








where ∆V is difference in volumes of a microneedle measured at different times (interval
is ∆t).
Numerical simulations of Equations (4.3) and (4.4) with initial conditions, Equa-
tions (4.5) and (4.6), have been performed using fourth order Runge-Kutta method. Results
with H0 = 0.5× 10
−3 m, θ = π
6
, kD = 10
−4 m/s, ρ=2 kg/m3, cs=1 kg/m
3 and α=1.5 are
plotted in Figure 4.7. In Figure 4.7, concentrations are denoted as dashed lines and mi-
croneedle heights are in solid lines. Each line passes through label that shows value of
k1 used in its simulation. Each simulation ends when H reaches zero. From the trend
observed in Figure 4.7, fast elimination of drug out of epidermis increases the dissolution
of the microneedle. In the context of Chapter 4, an applied electric current is expected to


































Figure 4.7 Effect of drug elimination rate constant on dissolution of soluble microneedle.
4.3 Mathematical Formulations and Simulations
Feasibility of the proposed transdermal drug delivery using soluble microneedle patch plus
electric current simultaneously has been indirectly proven through set of preliminary stud-
ies, although data obtained from in vivo experiments are not present. Therefore, the rest of
this chapter will be dedicated to development of mathematical model describing motion of
drug in epidermis, to computer-assisted simulation and to comments on future experimental
and manufacturing tasks.
4.3.1 Electrohydrodynamic Equations
An electrohydrodynamics is a class of studies in which effect of electric field on fluid
dynamics and/or species transport is investigated [89, 90, 91]. For example, attempts to
involve equations of electrohydrodynamics in dynamics of a falling liquid film down an in-
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clined plane have been made so far [92, 93, 94, 95]. Drug delivery system discussed in this
research also contains epithelial fluid and drug species under an applied electric field, and
thus, equations developed in electrohydrodynamics should be employed in mathematical
model. Equations already used in the analyses on iontophoresis [96, 97, 98, 99, 100] are
also based on the electrohydrodynamics.
Considering the involved transport mechanisms of drug molecules, diffusion, con-
vection and electromotive motion contribute to total flux such that
[Jtotal] = [Jdiffusion]+ [Jconvective]+ [Jelectromotive] . (4.10)
Square brackets are used to denote for vectors. Mass transfer only by diffusion in Equa-
tion (4.10) is called passive diffusion to emphasize that no external force is exerted to mo-
tions of drug molecules and transporting speed is commonly slow. The flux due to diffusion
follows the Fick’s law:
[Jdiffusion] =−D [∇C] , (4.11)
where D is apparent (or effective) diffusivity of drug through epithelial and C is drug con-
centration. The negative sign means that drug moves from high to low drug concentration,
regardless of choice of coordinate system. The nabla, ∇, stands for gradient in coordinates.
Flux of drug molecules by convection is directly proportional to concentration and velocity
of epithelial fluid, [u]:
[Jconvective] = C [u] . (4.12)
The electromotive motion is caused by the Coulomb’s force exerted between charged mat-
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ters. Such motion by applied electric field, [εE ], yields electric current (density) [I] such
that
[I] = q [εE] , (4.13)
where q is charge density. Permittivity of epithelial fluid, ε , is defined as εrε0 in which εr
is a dielectric constant of the fluid and ε0(=8.854×10
−12 F/m) is the electric constant. For
examples, dielectric constant is 1 for vacuum (or air) and 80.4 for water. Drug carrier is
space charge [94] (i.e., charged particle), and thus,
[Jelectromotive] = Cpµ [εE] . (4.14)
Here, p represents induced dipole moment of space charge and µ is its ionic mobility. Note
that the SI units of the dipole moment and the ionic mobility are C·m (C is Coulomb) and
m2
V·s , respectively.
By recalling Equation (4.10), the total flux of drug is rewritten as
[Jtotal] = −D [∇Ci]+C [u]+Cpµ [εE] . (4.15)
Applying the Gauss Theorem into Equation (4.15) yields partial differential equation gov-
erning motion of drug such that
dC
dt
= −∇ · Jtotoal = D∇
2Ci −∇ · (C [u])−∇ · (Cpµ [εE ]) . (4.16)




= D∇2C− ([u]+ pµ [εE]) · [∇C]−Cpµ [ε∇ ·E] . (4.17)






Since the space charge is induced by electric field, charge density can be written as
q = pC. (4.19)
The velocity of epithelial fluid also contribute to convective transport of drug, and








+q [εE] , (4.20)
where ρ and η are density and effective viscosity of fluid, respectively. Deriving Equa-
tion (4.20), effect of gravity or pressure drop can be ignored because epithelial fluid is









+ pC [εE] . (4.21)
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where ν = η
/
ρ is kinematic viscosity and has a unit of m
2s−1. In Equations (4.22) to (4.25),
the electric field is replaced by the electric potential using
[E] = −∇ ·φ , (4.26)















Lateral axes are named x and y, respectively, and vertical axis is z in Figure 4.1.
Dimensionless variables are obtained by introducing characteristic length and velocity of
the lateral axes, L0 and U0, and characteristic voltage of electrode, φ0, respectively. The
results are c = Ci
/
cs






, ūy = uy
/
U0
, ūz = uz
/
ξU0 and φ̄ =
φ/
φ0. Ratio of
the vertical to the lateral dimensions is ξ , and solubility of drug in the epithelial fluid is cs.
The dimensionless equations are obtained by plugging those variables into Equations (4.22)







































































































































, ratio of electromotive
motion to convective mass transport of drug molecule is represented by R = pµφ0
U0
, electro-





, momentum diffusivity to the mass diffusivity by
Sc = ν
D





























where dimensionless parameter is defined as N = kDL0
D
, and normalized density of drug in
microneedle is ρM =
ρs
cs
. Equation (4.33) holds only in the presence of microneedle. Once












In Equations (4.33) and (4.34), L (τ) means distance between surfaces of microneedle and









Equation (4.35) also holds only in the presence of microneedle, i.e., L (∞) → 1. The di-
mensionless dissolution rate constant is defined by Q = L0kD
DρM
. At the boundary between the
epidermis and the body, the perfect sink condition is assumed such that
c|z̄=1. (4.36)
Other boundary conditions necessary for simulations will be set up adequately upon
definition of geometry to be analyzed. In general, increase in dimension of simulation may
yield higher accuracy of analysis. However, complexity of simulation and demand on
computational resources increase as well. Therefore, many simulation-involved analyses
on drug delivery systems or other studies have been carried out in reduced (i.e., one- or
two-) dimensions. In the rest of this section, results of one-, two- and three-dimensional
simulations of the given problem have been presented. As stated above, computational
resources and wall-clock time of simulation increases with the dimension. Nevertheless,
the results of the case studies are compared. In addition, effective analytical strategies (i.e.,
accuracy and computer resources) are discussed.
4.3.2 Simulations of One-Dimensional Transport
The drug delivery domain in the one-dimensional study is defined by a line segment of
unit length, see Figure 4.8. The origin of the coordinate lies at surface of an electrode.
The center of the microneedle is located at x=1. Since the microneedles and the electrodes
are placed alternately in an array, another electrode is at x=2. However, the domain from
x=1 to x=2 will not be analyzed because of symmetry. The equations to be solved are
reduced forms of Equations (4.28), (4.29) and (4.32) by setting obtained derivative terms
101
with respect to y equal to zero and by combining the boundary condition at the end of the

















−Kc2 − kabc, (4.37)














Figure 4.8 Physical configuration used for one-dimensional simulation of the proposed
drug delivery system.
Equation (4.37) is subjected to Equation (4.33) until microneedle disappears due to
dissolution, i.e., L (τ) → 1, and then, to Equation (4.34) . Initial and other boundary con-
ditions are as follows. At the surface of the electrode, no flux (or the symmetry boundary











And at both ends, epithelial fluid does not escape the domain:
ū|x̄=0 = ū|x̄=L(τ) = 0. (4.39)
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Finally, the initial epidermis is drug-free and the epithelial fluid is not moving:
c|τ=0 = 0, (4.40)
and
ūx|τ=0 = 0. (4.41)
Computer program to solve the one-dimensional problem has been written in Math-
ematica® environment. In the solution procedure, L (τ) is discretized into a number of seg-
ments following rule of orthogonal collocation [20]. The rest region from L (τ) to 1 is out of
consideration. The simulation will give the drug concentration profile, velocity of epithelial
fluid and electric potential at adjoining points formed by adjacent segments, called collo-
cation points. In the orthogonal collocation method, partial differential equation (PDE),
e.g., Equations (4.37), and the ordinary differential equation (ODE) are reduced to a set
of ordinary differential equations and a set of algebraic equations, respectively. Although
Mathematica® provides built-in powerful integration tools, they are not implemented in
this simulation because the following features are not allowed:
Moving Boundary Problem Due to the dissolution, the domain, ranged from 0 to L (τ),
is expanding. This causes the absolute position of the collocation points to be shifted
toward the center of the microneedle at every time step in the integration, even though
their relative positions remain unchanged. Consequently, the concentration, veloc-
ity and electric potential should be updated at new collocation points using a linear
interpolation after each step.
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Implicit User-Defined Function The discretized governing equations are a set of ODEs
for concentration and velocity profiles, and a set of algebraic equations for electric
potential. In the integration of ODEs, the solutions to the set of the algebraic equa-
tions are used as if they were coefficients. In cases where the algebraic equations are
explicit (e.g., y = f (x)), it is possible to incorporate them into the built-in function
NDSolve. However, the algebraic equations for electric potential are implicit (e.g.,
f (x,y) = 0).
To show the electrical enhancement in drug delivery by a self-dissolving micronee-
dle patch, simulations are performed with various values of R, K and M while others are
fixed at Sc=0.01, P=0.1, Q=0.1, N=0.1 and kab=0.1. These numbers do not reflect exper-
imental particle motion through the skin as a result of iontophoresis. For example, there
have been reports on the occurence of electroosmotic flow as a significant factor in ion-
tophoretic transdermal drug delivery. However, the contribution of the electromotive flow
relative to the bulk fluid flow (i.e, R) has not been documented in this work. These model
parameters are selected for the purpose of the simulations. The values of R, K and M,
related to the electric field or the electric properties of system, are set equal to each other
as 0 (no electric current), 0.1 and 1. Initial radius of the microneedle is 0.2 so that length
of the epidermis, i.e., L (τ), is expanding from 0.8 to 1.0 as time passes. As a result,
fractional releases of drug into systemic circulation are estimated and demonstrated in Fig-
ure 4.9. According to Figure 4.9, the drug delivery is apparently enhanced by the applied
electric field. In this simulation, however, the elapsed times until complete dissolutions of
the microneedles are 2.056 in all cases. Even though the decreasing dissolution times are
observed with increasing electric field when smaller step size of time in simulation is used,
it is not suitable for validation of drug delivery enhancement scenario (electric field will
activate both mechanisms of diffusion and dissolution).
To magnify the effect of the electric field on the dissolution time, Two parameters

























Figure 4.9 Fractional release of drug at various intensities of the electric field calculated
through the one-dimensional simulations.
effect on concentration, respectively. Then, the dissolution times are estimated while R=M
are varied from 0 to 1. Numerical instability is observed for R and M greater than 1 in this
simulation. In the new simulation, K is fixed at 0.1 because K is related to the electrical
properties,and is helpful to identify the isolated effect of the intensity of the electric field.
Based on Figure 4.10, dissolution time is decreased as increasing electric field, and thus,
the drug delivery enhancement scenario is proved in this one-dimensional simulation.
Each set of simulations with different set of parameters can provide characteristic
information of the proposed drug delivery system: the first set of simulations is good for
showing the enhanced drug delivery in terms of the absorption but not suitable to distin-
guish the dissolution time, on the other hand, the second set is good for visualizing the
































Figure 4.10 Dissolution time with increasing electric field.
4.3.3 Simulations of Two-Dimensional Transport
The domain of two-dimensional simulation consists of the lateral (x; along skin) and verti-
cal (z; to depth of skin) axes, see Figure 4.11. In Figure 4.11, The center of base of conical
microneedle is located at (x, z)=(1, 0), and the apex faces to the systemic circulation (tri-
angular area shaded by lines). The base of electrode is placed at the origin (thickest line).
The height of microneedle is set as one half. To implement two-dimensional orthogonal
collocation technique, the square domain is first divided into 9 layers including the top
and bottom boundaries (dotted lines). The length of each line is determined by orthog-
onal collocation rule [20]. Every line is also divided into 9 collocation points using the
same rule (filled circles). The differential equations to be solved in this work are derived
from Equations (4.28), (4.29), (4.30) and (4.32) by setting the derivatives with respect to
y as 0. Discrete forms of those equations are set of 147 ODEs (=(7 internal collocation











Figure 4.11 Dimensionless domain for two-dimensional simulations.
In Figure 4.11, the top and bottom boundaries are set electrically insulated, and, for
boundaries denoted by the thick-dashed-vertical lines, electric potential as well as concen-
tration and velocities are symmetric. The perfect sink condition is used at the top where
the absorption of drug occurred while no flux exists at the stratum corneum (the bottom
line). No fluid-motion assumption is made at the top and bottom lines. At the electrode,
the electric potential is set to 1, and at the surface of microneedle, its value is 0.
According to the orthogonal-collocation discretization, there are 9 equations for
L (τ) such that
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where d is the depth of line and θ is the half angle of apex. After L (τ) reaches 1, Equa-
tion (4.42) no longer applies.
Two-dimensional simulations have been performed for τ=0 to 4 with the same val-
ues of the parameters used in the one-dimensional study. In addition, the ratio of the vertical
to the lateral dimensions of the domain, ξ , is set equal to 0.9, and θ = π
/
6. Concentrations
of drug at the selected times are plotted in Figures 4.12 through 4.15. For comparisons,
each figure contains two parts: the upper ones, or parts (a), show the concentrations in
the epidermis without electric field, while the lower ones, or parts (b), are the case where
electric field is applied, i.e., R=K=M=1. In those figures, the dissolving microneedles are
shown at the rightmost corners of surfaces (the corners look as if they were cut by a knife).
At τ=0.2 (Figure 4.12), the concentration increases in the beginning. At τ=1 (Figure 4.13),
it seems to reach the maximum. At τ=2 (Figure 4.14), the concentration decreases and
the microneedle has considerably shrunk. At τ=2.5 (Figure 4.15), the dissolutions of the
microneedles are almost completed and most drugs are already absorbed to the systemic
circulation. The noticeable observation is that the highest concentration, the darkest por-
tion of the surface, as well as the overall concentrations in the part (a) in Figure 4.12 are
greater than those in the part (b) of the same figure. This trend is also observed in the other
figures, Figures 4.13 to 4.13. It implies that the electric field lessens the drug concentration
near the microneedle and that the drug delivery has been enhanced by the electric field in
the sense that more drug has escaped from the epidermis, i.e., absorbed into the systemic
circulation.
Electrical enhancement of transdermal delivery through self-dissolving micronee-
dle patch is quantitatively presented in Figure 4.16. In Figure 4.16, the significant enhance-
























































































































































































Figure 4.15 Concentration surfaces at τ=2.5: (a) R=K=M=0, (b) R=K=M=1.
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a sub-axis of Figure 4.16. As discussed in the one-dimensional study, the electric field not
only activates the spread of drug along skin (along the secondary direction of drug delivery)
but also holds the drug within the epidermis (against the primary direction), see Figure 4.1.
This is the reason why the fractional releases get closer and closer to one another as time
passes. From Figure 4.16, it is recommended that the power supply be switched off before
τ=1.2 when the extent of the enhancement is still large. Otherwise, the benefit from the use
of the electric field will be lost. As a result, the additional expenses due to preparing and









































Figure 4.16 Fractional releases through self-dissolving microneedle patch at various in-
tensities of electric field in two-dimensional study.
The dissolution time in the two-dimensional study is 2.91 for all three cases. In-
deed, the results of the estimations of dissolution times show that dissolution rate visibly
increased only with stronger electric field (not shown). However, in order to visualize the
extremely small differences, much smaller size of time step in the fourth order Runge-
Kutta method should be used, which requires additional computational resources and time.
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Nevertheless, those small changes in the dissolution time may not be worth investigating
because it will produce no practical meaning.
4.3.4 Simulations of Three-Dimensional Transport
Domain of three-dimensional simulation is defined as a cube (the length of a side is 1). The
base (i.e., x-y plane at z=0) of the cube is placed on the surface of skin (or stratum corneum)
and the top face (at z=1) is the boundary between epidermis and body. The centers of bases
of conical microneedles are placed at (0,1,0) and (1,0,0) and the electrodes are located at
(0,0,0) and (1,1,0). The heights of microneedles and the electrodes are all one half. To
define the orthogonal collocation points in the space, the cube is sliced into 9 square planes
(including the top and the bottom faces) parallel to the base according to the orthogonal
collocation rule [20]. Since three-dimensional configuration of the given domain is very
complicated to draw, one square plane at the depth of γ, i.e., (x,y,γ), is representatively
shown in Figure 4.17. Based on these descriptions, the plane that is placed lower than
the tips of microneedles should contain two one-quarter circles (microneedles; the shaded
areas) at the points (1,0,γ) and (0,1,γ). The initial radii of those circles depend on the depth
of the plane, γ, such that
r = rb (1−2γ) , (4.43)
where rb is the radius of the base of microneedle. Equation (4.43) holds only when the
depth γ is less than one half, otherwise, r is zero (no microneedle). Although the dimension
of the electrode is similar to that of the microneedle, the electrodes are drawn as points at
(0,0,γ) and (1,1,γ) in Figure 4.17. The other area in the plane is filled with epithelial fluid.
The area filled with the epithelial fluid is divided into lines, i.e., L (τ = 0), the num-





















Plane at the Depth Γ
HΑ, Β, ΓL
LΒ,Γ=1- r - Β
r=rbH1-2ΓL
Figure 4.17 Top view of the square plane at the depth of γ in the domain of the three
dimensional study.
Then, the collocation points are located on each line. Supposed that a line, Lβ ,γ (τ = 0),






,γ) in the domain and either of its end is placed on the
circle, i.e., the surface of the microneedle, the length of the line which is occupied by the
epithelial fluid is obtained by
Lβ ,γ (τ = 0) = 1−
√
r−β . (4.44)
In the case where β is greater than one half, β in Equation (4.44) is replaced by (1−β).
The differential equations to be solved are Equations (4.28) to (4.32) and (4.35)
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without any modification. The thick dashed lines in Figure 4.17 denote the side walls of
the cubic domain at which the flux of drug, the velocities of the epithelial fluid and the
electric current are all zero due to the symmetry condition. At the thin arcs, which mean
the surfaces of the microneedles, Equation (4.33) is implemented. The thick dashed lines
cover the entire square except the portions of the electrodes. The boundary condition,
Equation (4.33), is removed as the microneedles disappear. The top and the bottom planes
of the cubic domain represent the boundary between the epidermis and the region where
the capillary vessels are found and the stratum corneum, respectively. At the top plate, the
flux of the drug, the velocities of the epithelial fluid and the electric current are set to zero.
At the bottom plate, a perfect sink condition is assumed. The velocities of the epithelial
fluid and the electric current are set to zero.
The three dimensional simulations are performed with the same values of the pa-
rameters as used in the one and two dimensional studies. A few illustrations are shown to
convey the outcomes of this research. In Figures 4.18 to 4.20, the concentration distribu-
tions at τ=0.2 and at three different depths (z=0 at the stratum corneum for Figure 4.18,
z=0.297 for Figure 4.19, and z=0.703 for Figure 4.20) are demonstrated. The concentra-
tions at upper layers are too low to lead to meaningful discussions. The upper axes of those
figures show the concentrations when no electrically-enhancing action is taken, and the




























































































































































Figure 4.20 Concentration profile at the depth γ=0.703 and at τ=0.2: (a) R=K=M=0, (b)
R=K=M=1.
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In Figures 4.18 to 4.20, the centers of the bases of the microneedles are located at
(1,0,0) and (0,1,0). Since the initial height of the microneedle is set one half, no micronee-
dle can be found in Figure 4.20. The highest concentration of part (a) in Figure 4.18 is
slightly but apparently higher than that of part (b) in the same figure (the leftmost region
of the concentration surface of part (a) crossed the line, but that of part (b) does not). This
trend is also observed in Figures 4.19 and 4.20, and shows that the applied electric field
lowers the drug concentration around the microneedle to activate the dissolution.
In Figure 4.21, the concentrations at the depth of 0.703 after a long time elapses, i.e.,
τ=1.4 are drawn: part (a) with no electric field, and part (b) with electric field. The main
observations are that the drug is more concentrated around the electrodes than where the
microneedles are placed, and that the overall concentration in the presence of the electrical
enhancement, part (b), is lower than that without it, part (a). These findings provide further
evidence of how drug delivery is enhanced by the presence of the electric field.
4.4 Electrically Enhanced Self-Dissolving Microneedle Patch
The aims of this investigation are 1) to propose a new enhanced transdermal delivery sys-
tem using an array of self-dissolving microneedles and microelectrodes on a patch, 2) to
quantitatively and qualitatively investigate the feasibilities of the proposed delivery plat-
form and the enhancement scenario, 3) to build up guidelines to future clinical experiments
for obtaining the accurate values of the cited physical properties, and 4) to build up guide-
lines to product design. Up to the previous section, the first two goals are achieved. The




















































The in vivo or in vitro experiments are very important for validating the mathematical
model. This study focused on simulations and dimensionless analyses because the physical
properties involved in the mathematical models are not available. Results of clinical ex-
periments, particularly designed for the proposed drug delivery platform, are also lacking
in the literatures. This section is committed to the use of the mathematical model and the
simulation in the generation of the clinical data and in the analysis on the obtained data to
estimate the values of the model parameters.
The elaborate fabrication method of an array of soluble microneedles is available in
the literature [11]. One of the formulation methods of the patch discussed in this research
is as follows. Electronic circuit is used as a patch substrate. A flexible design is desirable
to make sure that the patch attaches tightly to the curvy surface of a skin. On the electronic
circuit, an array of hard metal electrodes is placed in a way that the distance between the
adjacent (not diagonally) electrodes is twice that between the adjacent soluble microneedle
and the electrode on the complete array of the patch. The electrodes are interconnected
through the flexible circuit. Bores that will firmly hold the microneedles in place are made
by a micro-drilling tool. An array of soluble microneedles is fabricated following the pro-
cedures described in the previous researches [11]. An individual microneedle is taken from
the array, and it is nailed firmly (the sharp tip upward) to one of the bores prepared on
the flexible circuit substrate. In the end, the circuit is connected to a power supply for a
laboratory purpose, the serial connection of one or more dry batteries (providing 1.5 V per
each) may be recommended.
In clinical tests, the prepared self-dissolving microneedle and electrode patches are
placed on the skins of subjects. The blood samples are periodically taken from the subject.
The time intervals between samples are set by the experienced clinical scientists. The
serum concentrations of drug are measured from the samples and, hence, graphs of the
serum concentration vs. treatment time are prepared and ready to be analyzed.
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From the resulting graph, conventional pharmacokinetic analyses can be imple-
mented to estimate the values of the maximum serum concentration, Cmax, the time to reach
the maximum concentration, Tmax, and the area under the curve, AUC. Those pharmacoki-
netic parameters are taken into account when a product is designed. After this investigation,
additional task is suggested to be done. In other word, the estimations of the all parameters
involved in the model should be conducted by fitting the model-predicted serum concentra-
tion profile to the clinical data using the nonlinear regression or at least some trial-and-error
procedures if a high performance computer is not available. For example, the regression
yields a set of seven independent equations such that R = pµφ0
U0






















. The parameter, Q = L0kD
DρM
, are automatically de-
termined with N and ρM . There are seven independent constants (ρ, µ , p, D, ε , ν and kD).
The properties such as φ0, L0, ρs and ρM =
ρs
cs
can be determined by the fabrication method
























































These values can be used to predict the transdermal drug delivery through the proposed
platform with the different designs which are not yet explored by the clinical tests.
The in vivo validation of the drug delivery enhancement scenario can be conducted
by applying two patches simultaneously in one subject. One patch has the circuit con-
nected to the battery, and the other does not. Then, when a certain time has elapsed, the
two patches are simultaneously removed from the subject’s skin, and the shapes of the re-
maining microneedles are recorded for further comparison. To avoid any side effect due to
the multiple dosages, the size of the array in one patch may be reduced.
4.4.2 Product Design Guidelines
The parameters obtained from Equations. (4.45) to (4.51) can be used in the manufactur-
ing step of the product. As in the results of the three simulation studies, the predictions
with various designs can provide preliminary information on the design of the electrode-
mounted self-dissolving microneedle patch. Specifications such as the time to turn off the
device, the distance between microneedles, the dimensions of the conical microneedle, the
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size of the array, the electric potential of the electrode (it is related to the choice of the
battery), can be estimated.
4.5 Conclusions
The new transdermal drug delivery system using a self-dissolving microneedle enhanced by
an applied electric field is proposed in this study. The drug delivery platform is inspired by
the previous soluble microneedle therapy system and iontophoresis. For example, the shape
of the electrode is similar to that of the microneedle. The electrodes and the microneedles
are placed alternately in an array on the flexible patch substrate. At the beginning of the
treatment, the electrodes and the microneedles are inserted into the epidermis bypassing
the stratum corneum, and, at the sane time, the electric current is applied. The drug de-
livery is enhanced by the electric field which first attracts the drug molecules and results
in lower concentration around the microneedle. Consequently, the dissolution rate of the
microneedle will increase since the driving force of the dissolution (the difference between
the surrounding concentration and the solubility) is kept high. The delivery platform needs
to be validated using clinical test results. The rest of this research is dedicated to test the
concept with simple lab experiments, conduct simulations using the model and suggest
experimental guidelines for future clinical test.
The preliminary studies are conducted. The active diffusion of Indigo Carmine by
the electric field is first tested. Then the in vitro releases of benzocaine from lozenges
with/without an electric current are compared. The results of two pilot experiments show
that 1) the drug moves toward the cathode in a faster speed of the passive diffusion, 2) the
dissolution is affected by the electric field, and 3) the release is enhanced under the elec-
tric field. In the next investigation, the mathematical model of the dissolution of a conical
microneedle in a well-stirred container is set up to show the behaviors of the dissolving
microneedle and the concentrations in the epidermis during the treatment. Although the
mathematical simulations in the next sections have the same purposes, it is still impor-
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tant because more intuitive, concise and even faster analyses are possible with the simpler
model.
The mathematical equations describing the motion of drug and epithelial fluid, the
electric field and the size of the self-dissolving microneedle have been derived with the
relevant boundary conditions. The outcomes of the one dimensional simulation are 1) the
fractional release with the electric field is much faster than that without the electric field, 2)
the electric field accelerates the dissolution of the microneedle so that the dissolution time
decreases with increasing intensity of the electric field.
In two dimensional simulation, the concentration profiles are visualized to make
readers understand the detailed events that take place in the epidermis. A lower concentra-
tion under the electric field is observed around the microneedle compared to the case when
no electric field is applied. The fractional releases with/without the electric field are also
compared. The results show that, at the beginning of the treatment, the release seems to
be activated by the electric field, but, after a long time, the two release profiles are getting
closer. This is because the attraction of drug by the applied electric field accelerates the
dissolution but also prevents the drug from escaping the epidermis. This observation as
well as the time of dissolution in the one dimensional simulation lead to the conclusion that
the electric field should be removed after a certain time, e.g., it is about τ=1.2 based on the
analysis of the two dimensional simulation.
The results of the three dimensional simulation give another insight into the mech-
anisms of the drug delivery. In Figures 4.18 to 4.20, the behaviors of the concentration
profiles with/without the electric field are similar as expected from the previous simpler
simulations such that the lower concentration is observed when the electric field is applied.
The more significant aspect is shown in Figure 4.21 where the concentrations around the
electrode are higher than other places after a long time has lapsed, e.g., τ=1.4. This means
the drug is attracted by the electric field, and also implies that the continued electric field
may prevent the drug from being absorbed to the systemic circulation. Without the electric
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field, part (a) in Figure 4.21, such behavior is not found. Based on the findings from the
mathematical models and the simulations, guidelines for the clinical experiments and the
product design are made. The guidelines include the fabrication method of an array of the
self-dissolving microneedles and the electrodes on the patch substrate, properties that must
be measured, and how to estimate the unknown physical properties from the obtained data.
CHAPTER 5
CONCLUSIONS
The main purpose of this research is to provide a platform that will help improve research
on drug delivery. To achieve this goal, close collaborations with other researchers are neces-
sary along with the development of mathematical models of various drug delivery systems.
Several examples are provided in this work to show the advantages of theoretical studies.
Methods of incorporating the findings in experimental investigations are also outlined.
In the first project, a method to obtain the optimal intravenous dosage regimen is
discussed. The hybrid use of the already-invented dosage forms such as a bolus injection
and a constant rate infusion can minimize the time it takes to achieve a desired therapeutic
effect of a drug with the guaranteed safety. The investigation used a two-compartment
pharmacokinetic model to develop the optimal dosage regimens of the drug theophylline.
In the second project, the design problem of the transdermal drug delivery patch
assisted by an external heating device is studied. The heating pad has been already used
in many oriental countries to encourage the therapeutic effect of the drug. However, the
controlled release of drug from the patch by the heating pad has never been discussed, even
though it is very important for preventing accidental overdose. The mathematical model
allows the control and thus the optimal design of the corticosterone delivery system by
introducing the design factors: the mass of the heating pad (MS), the overall heat transfer
coefficient (OH), the initial reaction rate (IR) and the initial corticosterone concentration
(IC). The investigation reveals the optimal values of those factors as well as the relative
importance (the priorities in the design that maximizes the therapeutic effect when limited
resource is provided): IC>MS>IR>OH.
The last research deals with a proposed drug delivery system. In that prototype,
self-dissolving microneedles are used to bypass the stratum corneum, and an electric field
is simultaneously applied to the epidermis to enhance diffusion and dissolution. This is an
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advanced form of the hybrid system of the soluble microneedle plus iontophoresis in the
sense that the electrodes are also inserted into the epidermis as solid microneedles. The
work should analyze the problem in the absence of clinical test data and known electro-
hydrodynamic properties. Therefore, dimensionless analyses, based on the results of the
one-, two- and three-dimensional simulations, are only used to decipher the drug delivery
in the platform. The key outcomes of the research are that the applied electric field activates
drug delivery by encouraging the diffusion of drug in the epithelial fluid and, consequently,
accelerating the dissolution. At some time, the electric field needs to be removed in or-
der to allow the drug to be absorbed into the systemic circulation. Based on these results,
guidelines for the future experiments and the products are suggested.
The three research projects have successfully provided materials to show the advan-
tages of the mathematical models and the computer simulations in the design and control
of drug delivery systems. This work can be used, in conjunction with experimental data, by
researchers around the world to further the development of efficient drug delivery devices
and improved administration protocols.
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